



# Tumor Microenvironment Stress and Stress Adaptation Mechanisms

Qianqian Zhou<sup>1</sup>, Jilong Wang<sup>2,\*</sup><sup>1</sup>School of Clinical Medicine, Wenzhou Medical University, Wenzhou, 325000, China<sup>2</sup>School of Life Science, University of Science and Technology of China, Hefei, 230011, China

\*Corresponding author: Jilong Wang, wangjilong136@126.com

## Article history

Received: 23 November 2025

Revised: 10 February 2026

Accepted: 11 February 2026

Published online: 12 February 2026

## Keywords

Tumor microenvironment stress

Stress adaptation

Hypoxia

Oxidative stress

Endoplasmic reticulum stress

Metabolic reprogramming

Mechanotransduction

**Copyright:** © 2026 by the authors. This article is published by the ETERNO PRESS SDN. BHD. under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0): <https://creativecommons.org/licenses/by/4.0/>

## Abstract

The tumor microenvironment (TME) constitutes a highly dynamic and interactive complex ecosystem, whose core components include tumor cells, stromal cells, immune cells, and an intricate network of signaling molecules. A prominent characteristic of this environment is the presence of multiple tumor-intrinsic stress responses, including hypoxia, oxidative stress, endoplasmic reticulum (ER) stress, metabolic stress, and mechanical stress. These stressors do not act in isolation but act synergistically to form a unique microenvironmental stress field, ultimately serving as a key biological engine that drives tumorigenesis, promotes disease progression, and induces therapeutic resistance. Emerging evidence highlights that targeted modulation of TME stress signaling pathways can not only suppress tumor growth but also remodel the immunosuppressive landscape, thereby augmenting anti-tumor immunity and achieving a synergistic “stress induction-immune activation” effect. This review provides a comprehensive synthesis of the molecular mechanisms underlying TME stress, adaptive strategies employed by tumor cells, and recent therapeutic advances centered on stress regulation. By integrating mechanistic insights with translational perspectives, this article aims to offer a foundational framework for developing novel combination therapies in oncology.

## 1. Introduction

As a multidimensional regulatory system, the tumor microenvironment (TME) comprises the tumor cells themselves, diverse stromal cell populations (e.g., fibroblasts, endothelial cells), immune cell subsets, the three-dimensionally reticular extracellular matrix (ECM), and a dynamically cross-linked signaling molecule network. Far from being a simple cellular assembly, this complex system forms a sophisticated regulatory network through dynamic interactions between cells, matrix, and molecules, acting as an irreplaceable “ecological hub” that governs tumor initiation, malignant progression, and therapeutic response [1]. Within this highly heterogeneous and dynamically evolving ecosystem, tumor cells and the microenvironment engage in continuous and complex interactions, collectively shaping a local milieu characterized by multiple stress features, such as hypoxia, nutrient deprivation, oxidative stress, endoplasmic reticulum stress, metabolic stress, and mechanical stress. Such stress responses not only constitute a core driving force for the malignant progression of tumors, but also profoundly reshape the functional spectrum of immune cells. Through multiple mechanisms including impairing antigen presentation efficiency, lowering the activation threshold of effector cells, and inducing the differentiation shift toward regulatory cells, they ultimately foster an

immune-escape microenvironment characterized by disabled immune surveillance and a tolerogenic niche that renders therapeutic intervention ineffective [2,3].

Over the past decade, with breakthrough advances in the multidimensional dissection of the tumor microenvironment, a growing number of scholars have reached a strategic consensus: precisely targeting the endogenous stress response networks and dynamic adaptation modules within the TME can enable multidimensional innovations in antitumor strategies. Such targeted interventions not only effectively curb tumor proliferation by blocking aberrant signaling cascades, but more crucially, can reshape the ecological architecture of the immunosuppressive microenvironment, ultimately remodeling an “active immune microecosystem” that favors host antitumor immune responses. This approach ultimately achieves a “stress induction-immune activation” dual-strike effect [4-9].

While previous reviews have addressed individual stress pathways, there remains a need for an integrated analysis that elucidates how these stresses interact and converge to shape tumor evolution and immune evasion. This review aims to fill that gap by systematically examining the molecular mechanisms of TME stress, the adaptive responses of tumor cells, and emerging therapeutic strategies targeting these pathways. We further highlight

the conceptual innovation of combining stress modulation with immunotherapy to achieve dual anti-tumor effects, offering a forward-looking perspective for next-generation combination regimens.

## 2. Stressors

The TME is essentially formed by the non-tumor cellular components within tumor tissue and the signaling molecules they secrete [10]. This system exhibits the following typical characteristics: a hypoxic microecological niche (abnormally remodeled oxygenation gradient) [11], nutrient deprivation (depletion of metabolic substrates) [12], an oxidative stress-enhanced zone (accumulation of reactive oxygen species) [13], an acidotic microenvironment (imbalanced  $H^+$  concentration) [14], and a domain of interstitial fluid pressure imbalance (abnormally elevated hydrostatic pressure) [15]. These stressors do not act independently; instead, through crosstalk among complex molecular modules including the hypoxia-inducible factor (HIF) signaling axis, lactate shuttle metabolic pathway, vascular endothelial growth factor (VEGF) dynamic gradient, and PD-1/PD-L1 immune checkpoint, they dynamically adjust the stress threshold of the microenvironment at different stages of tumor progression, enabling malignant progression of tumors via stress adaptation [16].

### 2.1 Hypoxia

Hypoxia constitutes a central and defining feature of the TME. It arises from two primary factors: firstly, the dysfunctional and malformed tumor vasculature fails to provide adequate oxygen delivery; secondly, the rapid proliferation and heightened metabolic demands of tumor cells vastly outstrip the available oxygen supply. This imbalance creates pervasive regions of oxygen deficiency [17-19]. Furthermore, TME remodeling (such as ECM stiffening and elevated interstitial fluid pressure (IFP)) compresses blood vessels, exacerbating hypoxia [20]. Hypoxia alters the expression levels of genes regulating processes like metabolism [21,22]. The interaction of hypoxia signaling with other cellular pathways promotes malignant behaviors, including proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and enhances resistance to immunotherapy, chemotherapy, and radiotherapy [23-25].

### 2.2 Nutrient Deprivation

Under normal oxygen tension, mammalian cells primarily rely on mitochondrial oxidative phosphorylation (OXPHOS), the "molecular energy factory", to efficiently synthesize ATP. This process consumes oxygen and releases carbon dioxide, consistent with classic metabolic theory. In contrast, malignant tumor cells exhibit a striking metabolic reprogramming: even under normoxic conditions, they preferentially activate an "aerobic glycolysis engine". Through aberrantly enhanced glycolysis, glucose is converted to lactate at a much higher rate than in normal cells, accompanied by massive ATP production. This

seemingly inefficient metabolic strategy actually represents "metabolic wisdom" evolved by tumor cells to adapt to hypoxic microenvironments, resist oxidative stress, and establish an immunosuppressive niche, widely known in biology as the "Warburg effect" [26]. While oxidative phosphorylation generates 36-38 ATP per glucose molecule, glycolysis yields only 2. To compensate and fuel their rapid proliferation, tumor cells exhibit a voracious glucose uptake from the TME [27,28]. However, the abnormal structure and functional insufficiency of the tumor vascular system lead to inefficient delivery of nutrients such as glucose, amino acids, and fatty acids [29]. Simultaneously, the rapid proliferation rate of tumor cells outstrips the nutrient supply speed, and the rapid metabolism driven by the Warburg Effect rapidly depletes local microenvironmental glucose and amino acids, creating a "nutrient desert". Specific cell types further exacerbate nutrient deprivation; for example, tumor cells with high IDO expression degrade tryptophan, and myeloid-derived suppressor cells (MDSCs) deplete arginine via arginase 1 (ARG1), thereby selectively inhibiting T cell functions that depend on these amino acids, while tumor cells can adapt to nutrient deprivation through alternative metabolic pathways [30-32]. Lactate accumulation leads to TME acidification (low pH), which not only inhibits immune cell functions (such as T cells and NK cells) but also promotes the activity of immunosuppressive cells like regulatory T cells (Tregs) and MDSCs, facilitating immune evasion [33]. The acidic environment can also activate matrix metalloproteinases, promoting ECM degradation and thereby enhancing tumor invasion and metastasis [34,35]. Additionally, a glucose-deprived microenvironment prevents T cells from effectively proliferating, secreting cytokines (like  $IFN-\gamma$ ), and exerting cytotoxic effects, ultimately leading to the loss of anti-tumor immune function [36].

### 2.3 ROS Imbalance

Within the TME, reactive oxygen species (ROS) form a sophisticated oxidative stress network, whose core components include superoxide anion ( $O_2^-$ ), hydroxyl radical ( $\cdot OH$ ), hydrogen peroxide ( $H_2O_2$ ) [37], and lipid hydroperoxide (LOOH) [38]. These molecules are dynamically balanced through the synergy of multidimensional stressors. The three major sources of ROS are: OXPHOS imbalance caused by metabolic reprogramming in tumor cells, abnormal activation of NADPH oxidase due to disordered signaling pathways, and oxidative bursts triggered by cyclic hypoxia-reoxygenation fluctuations [39]. As the "dual energy-oxidation hub" of tumor cells, mitochondria continuously generate ROS via the OXPHOS pathway, forming a self-reinforcing vicious cycle: ROS burst - mitochondrial DNA (mtDNA) damage-respiratory chain dysfunction-further ROS burst [40]. Meanwhile, cancer-associated fibroblasts (CAFs) secrete oxidative molecules such as  $H_2O_2$ , establishing "oxidative stress microdomains" in the extracellular matrix, which directly stimulate tumor cell proliferation, invasion, and activation of the EMT program [41]. The biological

effects of ROS display a concentration-dependent biphasic regulation pattern. At moderate to high concentrations, ROS act as a "signaling switch": they drive malignant progression by activating proliferation-related pathways including PI3K/AKT and MAPK/ERK, while stabilizing HIF-1 $\alpha$  to promote angiogenesis and metabolic reprogramming. In contrast, ROS at suprathreshold concentrations function as a "cytotoxic weapon", directly causing cell damage and death by inducing DNA double-strand breaks, protein oxidative modification, and lipid peroxidation.

Simultaneously, they establish a dual barrier of "oxidative suppression and immune escape" by inhibiting T-cell receptor (TCR) signaling, attenuating the cytotoxic activity of natural killer (NK) cells, and inducing regulatory T-cell (Treg) differentiation [42,43]. Such a multidimensional regulatory network, spanning from molecular bursts to cell fate determination, profoundly underscores the core strategic role of ROS in the construction of the tumor niche. The sophistication of the TME lies in maintaining ROS within a "sweet spot" beneficial for tumor cells but detrimental to immune cells. The so-called "imbalance" stems not only from increased ROS production but more crucially from alterations in the antioxidant defense system. Many tumor cells activate the nuclear factor erythroid 2-related factor 2 (NRF2) pathway, upregulating antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), thereby maintaining ROS at levels conducive to proliferation while avoiding toxicity—a form of "pre-adaptation" [44,45]. In contrast, immune cells infiltrating the TME, such as effector T cells, often have insufficient antioxidant capacity and lower NRF2 activity, making them more susceptible to ROS-mediated functional inhibition and apoptosis [46]. When the antioxidant defense of tumor cells surpasses that of immune cells, a ROS imbalance favorable for tumor progression is established.

## 2.4 Mechanical Stress

Uncontrolled tumor cell proliferation elevates cellular density, generating solid stress through direct physical compression between cells [47]. This direct physical contact and compression between cells constitute a major source of solid stress, directly affecting cell morphology, division processes, and viability [48-50]. Activated CAFs extensively synthesize and secrete ECM components (such as collagen, fibronectin), leading to ECM over-deposition [51]. Enzymes like lysyl oxidase (LOX) promote cross-linking between collagen and elastic fibers, significantly enhancing ECM stiffness and mechanical tension [52,53]. This "stiffening" of the ECM is one of the most representative features of the tumor mechanical microenvironment [54,55]. Simultaneously, the structural arrangement of ECM fibers changes significantly, typically becoming thicker and more linearly aligned, forming a "highway" network conducive to cancer cell migration [56,57]. In terms of vasculature, abnormal tumor vascular structure, increased permeability, coupled with impaired lymphatic drainage, lead to massive leakage and accumulation of

plasma components in the tumor interstitium, significantly raising IFP [15]. This sustained high hydrostatic pressure not only severely hinders the effective delivery of anticancer drugs and the infiltration capacity of immune cells but also further drives malignant tumor progression [49,58,59].

Collectively, these stressors do not act in isolation. Instead, they interact TME to form a synergistic milieu that promotes tumor survival, invasion and immune evasion. For instance, hypoxia exacerbates oxidative stress and alters the stiffness of the ECM, while metabolic byproducts such as lactate further acidify the microenvironment and suppress immune function, among other effects. This interconnected stress network highlights the clinical imperative for multi-targeted therapeutic strategies that intervene in the TME as an integrated system, rather than targeting individual signaling pathways in isolation.

## 3. Stress Responses and Adaptive Strategies


The concept of TME stress encompasses the adaptive and maladaptive reactions elicited within tumor cells and their surrounding milieu when confronted with diverse internal and external challenges. Predominant forms include hypoxic, oxidative, endoplasmic reticulum, metabolic, and mechanical stress. In concert, these stress axes exert profound influence over the entire cancer lifecycle—from inception and local expansion to metastatic dissemination—while also serving as major contributors to the failure of therapeutic interventions [60-63].

### 3.1 Hypoxic Stress and Adaptive Strategies

Hypoxic stress in the TME is a core feature of malignant tumors, primarily driven by oxygen insufficiency due to aberrant vasculature and high cellular demand (Figure 1). The central adaptive response is orchestrated by hypoxia-inducible factors (HIFs), notably HIF-1 $\alpha$  and HIF-2 $\alpha$  [5,64]. In normoxia, HIF- $\alpha$  subunits are prolyl hydroxylated by PHDs, marking them for rapid ubiquitination and proteasomal degradation. Under hypoxic conditions, PHD activity is suppressed, leading to HIF- $\alpha$  stabilization, nuclear translocation, and dimerization with HIF- $\beta$ . This complex then binds to hypoxia response elements (HREs) in DNA, initiating the transcription of a broad program of genes essential for hypoxic adaptation [65,66]. HIF-regulated genes participate in multiple processes: (1) Metabolic reprogramming (Warburg Effect): HIF-1 $\alpha$  upregulates glycolytic enzymes (such as hexokinase, phosphofructokinase, LDH), shifting tumor cells towards glycolysis for energy production even when oxygen is sufficient [67]. (2) The angiogenesis regulatory axis: HIFs act as a "molecular switch" that precisely activates pro-angiogenic signaling modules such as VEGF in the hypoxic microecosystem, triggering the remodeling of the neovascular network within tumor tissue. Through dynamic processes including endothelial cell proliferation and migration, basement membrane remodeling, and pericyte recruitment, aberrant vascular loop structures and a leaky vascular bed are formed. This

remodeling not only meets the oxygen and nutrient demands for rapid tumor proliferation but also further promotes tumor invasion and metastasis [68,69]. HIF-2 $\alpha$  promotes clear cell renal cell carcinoma growth via erythropoietin (EPO) and angiopoietin (ANG); its inhibitor Belzutifan has received clinical approval [70,71]. (3) Proliferation and Survival: HIFs regulate the expression of cell cycle proteins and apoptosis-related genes, enhancing survival [72]. Hypoxia can induce cells into a quiescent state and confer stem cell-like properties [73,74]. It also promotes EMT, enhancing migration and invasion capabilities [75]. Tumor cells under hypoxia secrete large amounts of hypoxia-induced tumor-derived exosomes (hiTDExs), whose unique cargo (e.g., miRNAs, proteins) mediates intercellular communication within the TME, promoting immune evasion, angiogenesis, and therapy resistance [76-78]. Hypoxia

also remodels multiple cell types in the TME, synergistically promoting progression and resistance [79-81]: it inhibits T cell metabolism and function [82]; induces CAF formation (secreting immunosuppressive factors like TGF- $\beta$ , PGE2, IL-6) [83]; recruits MDSCs and Tregs, exacerbating immune evasion [84]. ECM produced by CAFs forms a physical barrier, impairing NK cell activity [85,86]. Hypoxia also alters ECM components (like collagen, hyaluronic acid), increasing tissue stiffness and forming barriers to drug diffusion and immune cell infiltration [87]. Studies find that hypoxia alters key signature genes of glioma-associated microglia/macrophages (GAMs), enhancing their immunosuppressive properties [88]. While hypoxia can indirectly influence redox balance (e.g., via mitochondrial dysfunction), the primary sources and signaling roles of ROS constitute a distinct stress axis.




**Figure 1.** Hypoxia induces multifaceted effects on cancer cells, encompassing alterations in cell fate, genetics, metabolism, and clinicopathological behaviors. It promotes genetic instability and DNA damage, modulates ROS and metabolic pathways, and leads to extracellular acidification. Hypoxia also inhibits apoptosis, enriches cancer stem cells, and drives EMT, thereby enhancing invasion, metastasis, and resistance to therapies [23].

### 3.2 Oxidative Stress and Adaptive Strategies

In contrast to the oxygen deficiency defining hypoxia, oxidative stress in the TME arises from an imbalance between the production and clearance of ROS, encompassing molecules such as superoxide anion ( $O_2^-$ ), hydroxyl radical ( $\cdot OH$ ), and hydrogen peroxide ( $H_2O_2$ ) [37-39]. This state is fundamentally driven by elevated ROS generation—primarily from mitochondrial oxidative phosphorylation, aberrant oncogenic signaling, and stromal cell activity—coupled with altered antioxidant defenses [40,41,89,90]. Due to their rapid proliferation capacity and specific metabolic patterns, tumor cells typically exhibit elevated basal ROS levels [91,92]. The pathological state caused by abnormally high ROS is oxidative stress, accompanied by imbalanced redox signaling and oxidative damage to biomolecules [93]. As a core hallmark of cancer, it is closely related to tumor proliferation regulation and microenvironment remodeling [94]. Elevated ROS levels activate various

signaling pathways by oxidizing specific amino acid residues in signaling proteins, promoting tumor cell proliferation and survival [95] (Figure 2). For example, the oxidative microenvironment centered on  $H_2O_2$  triggers the unwinding of the "molecular latch" in the three-dimensional conformation of protein tyrosine phosphatase 1B (PTP1B) by targeting and modifying the Cys215 cysteine residue. This chemical modification leads to dynamic rearrangement of the PTP1B catalytic pocket and markedly attenuates its substrate-binding capacity, initiating a cascade of "phosphatase activity inhibition-signaling pathway activation". Specifically, inactivation of PTP1B releases the dual inhibitory constraints on two critical axes: the survival axis composed of insulin receptor substrate 1 (IRS-1)-phosphatidylinositol 3-kinase (PI3K)-phosphoinositide-dependent protein kinase 1 (PDK1)-AKT, and the proliferation axis consisting of leptin, Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3).



**Figure 2.** Schematic diagram illustrating how mitochondrial ROS (mtROS) stress promotes cancer cell survival and shapes an immunosuppressive TME to drive tumorigenesis. mtROS are mainly generated by mitochondrial aerobic respiration and metabolic enzymes. The chaperone Lon, a key component of mitochondrial protein quality control, interacts with NDUFS8 in Complex I and with PYCR1 to enhance mtROS production, thereby promoting proliferation and inflammation. The HSP60-mtHSP70-Lon complex sequesters p53 and stabilizes the mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCLX), inhibiting apoptosis and increasing cisplatin resistance under ROS stress. mtROS also cause oxidative damage to mtDNA, activating the cGAS–STING–IFN pathway and upregulating PD-L1 expression, which suppresses T-cell activation. ROS and hypoxia upregulate Lon, triggering the release of extracellular vesicles (EVs) carrying mtDNA and PD-L1. These EVs stimulate macrophages to produce IFN and IL-6, further impairing T-cell immunity. Moreover, ROS induce NF-κB-dependent inflammatory cytokines (e.g., IL-6, TGF-β, VEGF), polarizing macrophages, dendritic cells (DCs) and T cells toward immunosuppressive phenotypes (e.g., TAMs, regulatory DCs, Tregs). Ultimately, mtROS establish an immunosuppressive TME that facilitates immune escape, cancer cell survival, and EMT/metastasis [94].

This molecular logic chain of "oxidative modification-conformational unlocking-pathway activation" establishes a "survival signal enhancement loop" and a "proliferation command amplification network" in cancer cells.

Ultimately, through multidimensional effects including enhanced glucose uptake, suppressed apoptotic programs, and promoted ribosome biogenesis, it drives the adaptive survival and malignant proliferation of cancer cells under oxidative stress [96-98]. ROS also inhibits protein tyrosine phosphatase (PTP) activity, preventing epidermal growth factor receptor (EGFR) dephosphorylation, continuously activating EGFR signaling, which then promotes proliferation and inhibits apoptosis via the Ras–RAF–MEK–ERK pathway [99-101]. ROS affects the DNA-binding activity of the NF-κB subunit p50 and regulates RelA (p65) phosphorylation; meanwhile, kinases like p38α MAPK, ATM, ERK mediate p53 phosphorylation, disrupting cysteine clusters in its DNA-binding domain, weakening p53's transcriptional activity, thereby promoting proliferation and inhibiting apoptosis [102,103]. Extensive crosstalk exists between these pathways, enabling tumor cells to integrate multiple stress adaptation signals, driving tumor progression [6]. A key adaptive strategy for tumor cells is to harness this

pro-tumorigenic signaling while avoiding cytotoxic ROS levels, achieved by upregulating antioxidant systems such as the NRF2 pathway [44,45]. In contrast, immune cells infiltrating the TME, such as effector T cells, often have insufficient antioxidant capacity and lower NRF2 activity, making them more susceptible to ROS-mediated functional inhibition and apoptosis [46]. When the antioxidant defense of tumor cells surpasses that of immune cells, a ROS imbalance favorable for tumor progression is established.


Beyond autonomous regulation by tumor cells, ROS also plays a key role in the interaction between tumor cells and the microenvironment: excessive ROS causes DNA damage, genomic instability, and oxidative damage to biomolecules, activating oncogenic signals and promoting TME remodeling [6]. Mitochondria-derived ROS are important mediators of tumor initiation and progression, affecting proliferation, migration, invasion, angiogenesis, and inflammatory responses [94]. ROS mediates interactions between cancer cells, stromal cells, and immune cells via signaling pathways. Inflammation and oxidative stress form a complex network jointly influencing tumorigenesis and development [104-106]. Oxidative stress can induce EMT, promoting invasion and metastasis [107]. High levels of ROS directly inhibit T cell proliferation, differentiation, and effector function

[108,109], and promote macrophage polarization towards the M2 phenotype, enhancing immunosuppression, thereby promoting tumor immune evasion [104]. It is noteworthy that hypoxia can modulate the oxidative stress landscape (e.g., by affecting mitochondrial respiration and ROS generation); however, the core mechanisms and consequences of redox imbalance remain a distinct hallmark of the TME, as outlined above.

### 3.3 Endoplasmic Reticulum Stress and Adaptive Strategies

Protein processing, modification, and folding in the endoplasmic reticulum (ER) are tightly linked regulatory processes determining cell function, fate, and survival [110]. The uncontrolled proliferation of malignant tumor cells creates an unfavorable microenvironment, disrupting calcium/lipid homeostasis for various cells in this environment, impairing ER protein folding capacity in both tumor cells and infiltrating immune cells [111]. This promotes the accumulation of misfolded/unfolded proteins within the ER, triggering the unfolded protein response (UPR), thereby inducing ER stress [112]. The UPR in the endoplasmic reticulum is essentially a homeostatic repair program initiated by cells to restore the protein-folding capacity and secretory function of the ER (Figure 3). This repair program is intelligently regulated: Under transient stress, the UPR re-establishes homeostasis by upregulating the expression of molecular chaperones, suppressing global protein translation, and enhancing the degradation of misfolded proteins. However, when persistent stress exceeds a threshold, the repair network triggers a homeostatic collapse-to-apoptosis switch: via activation of the CHOP transcription factor, opening of the Bax/Bak mitochondrial permeability pore, and amplification of the caspase cascade, it ultimately executes the emergency decision of repair failure followed by programmed cell death [113,114]. The UPR is primarily regulated by three ER-resident sensors: inositol-requiring enzyme 1 $\alpha$  (IRE1 $\alpha$ ), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6). These three branches can control multiple pro-tumor characteristics in cancer cells while dynamically reprogramming the functions of innate and adaptive immune cells [115-117]. Therefore, aberrant activation of ER stress sensors has become a key regulator of tumor growth, metastasis, and response

to chemotherapy, targeted therapy, and immunotherapy [118,119]. The UPR promotes adaptation and survival through its three branches: (1) IRE1 $\alpha$ -XBP1 axis: IRE1 $\alpha$  splices XBP1 mRNA to produce the active transcription factor XBP1s, upregulating ER chaperones (like GRP78) and lipid synthesis genes, promoting ER expansion [120]. (2) PERK-eIF2 $\alpha$  axis: PERK phosphorylates eIF2 $\alpha$ , inhibiting global protein synthesis, while inducing ATF4 transcription, upregulating antioxidant genes (like glutathione synthetase) and autophagy-related genes [121]. (3) ATF6 axis: ATF6 is cleaved in the Golgi apparatus, releasing an active fragment that upregulates chaperones and ER-associated degradation (ERAD) components [122-124]. Persistent and severe stress shifts towards pro-apoptotic pathways such as upregulating CHOP [125]. However, many tumors evade UPR-induced apoptosis by upregulating chaperones/anti-apoptotic proteins, thus utilizing the UPR to promote their own survival [8,126,127]. ER-mitochondria communication is important: ER stress causes abnormal Ca<sup>2+</sup> release, leading to mitochondrial calcium overload, permeability transition pore opening, cytochrome c release, and apoptosis. ER stress also causes ROS accumulation, impairing mitochondrial function, forming a vicious cycle; mitochondrial ROS can feedback to exacerbate the UPR. This bidirectional regulation enhances the tumor's antioxidant capacity and metabolic plasticity [128-130]. There is crosstalk between mitochondrial UPR (UPRmt) and ER UPR (UPRER); for example, ATF5 (a key regulator of UPRmt) and ATF4 (a downstream molecule of UPRER) share transcriptional regulatory targets, coordinating cellular adaptive responses under metabolic stress [131]. ER stress regulates the immune microenvironment: it induces CD8<sup>+</sup> T cell dysfunction and exhaustion (upregulating PD-1, 2B4), induce macrophage polarization (upregulating MRC1, CD206) and regulates NK cell function and dendritic cell maturation via pathways like c-Myc [126,132,133]. It promotes immunosuppression: enhancing the immunosuppressive function of TAMs; potentially affecting immunosuppression by regulating TREM2 in myeloid cells [134,135]. It affects immune checkpoint dynamics: overactivation of immune checkpoint proteins (ICPs) impairs anti-tumor immunity, even induced suppression may impair the efficacy of immune checkpoint inhibitors (ICIs) [136].



**Figure 3.** Dynamic regulatory network of the UPR triggered by ER stress. Upon aberrant accumulation of misfolded proteins in the ER lumen, three core sensor modules—ATF6, PERK, and IRE1—are synchronously activated and initiate sophisticated signaling cascades. ATF6 undergoes proteolytic cleavage during its translocation from the ER to the Golgi apparatus, releasing a transcriptionally active cytoplasmic domain. PERK induces the selective translation and activation of ATF4 by catalyzing the phosphorylation of eukaryotic initiation factor 2 $\alpha$  (eIF2 $\alpha$ ), which in turn regulates the expression of downstream targets such as NRF2. IRE1 splices the precursor mRNA of X-box binding protein 1 (XBP1) via its endoribonuclease activity to generate a transcriptionally active spliced isoform, driving the coordinated expression of genes involved in protein folding, quality control, and secretion. These crosstalking signaling pathways converge in the nucleus and regulate the transcriptional program of key effector molecules including heat shock protein 47 (HSP47) and non-muscle myosin IIA, thereby maintaining a dynamic balance in cell fate decisions among apoptosis, survival, and autophagy, while also modulating lipid synthesis and metastasis-related pathways. Through multidimensional signal integration, this adaptive response program initiates homeostatic reprogramming to restore ER function under transient stress, or directs cells toward programmed elimination under persistent ER stress [23].


### 3.4 Metabolic Stress and Adaptive Strategies

The confluence of hypoxia, nutrient scarcity, and acidosis—hallmarks of the TME—establishes a pervasive state of metabolic stress [137]. This condition acts as a dual regulator: it drives further metabolic rewiring in tumor cells and imposes profound functional constraints on tumor-infiltrating immune cells, thereby critically determining the efficacy of anti-tumor immunity and therapeutic success [9,138]. Under TME metabolic stress conditions, tumor cells evolve various adaptation mechanisms [139]. For example, facing nutrient deprivation such as glucose deprivation, tumor cells can upregulate glutathione (GSH) synthesis to resist oxidative stress, thereby enhancing their viability and resistance to nutrient starvation therapies [140]. Clinical studies have revealed that high expression of interleukin-1A (IL-1A) activates the glutathione synthesis engine in tumor cells. By upregulating the expression of  $\gamma$ -glutamylcysteine synthetase ( $\gamma$ -GCS) and enhancing the activity of cystine transporters, it drives the abnormal accumulation of GSH and constructs an oxidative defense barrier. This metabolic reprogramming strategy endows oral squamous cell carcinoma (OSCC) cells with potent antioxidant capacity. It not only neutralizes oxidative damage induced by chemotherapeutic agents, but also generates a superimposed survival advantage by inhibiting ferroptosis, maintaining mitochondrial functional

stability, and promoting DNA damage repair. Notably, enhanced GSH synthesis is significantly negatively correlated with clinical prognosis. Patients with high GSH levels generally exhibit increased tumor invasion depth, elevated lymph node metastasis rate, and shortened overall survival, making it an independent indicator of poor prognosis [141]. Tumor cells also respond to stress through ECM remodeling and metabolic interdependence with other cells: CAFs exhibit strong survival capabilities under stress conditions, releasing nutrients into the microenvironment via catabolism for tumor cell uptake and utilization, thereby helping tumor cells adapt to the harsh environment [142]. Furthermore, lipid metabolic reprogramming is another important strategy for tumor cells to adapt to TME stress—lipids, as energy sources and cell membrane components, play a key role in tumor initiation and progression [143,144]. Tumor cells typically undergo lipid metabolic reprogramming (Figure 4), characterized by increased lipid uptake, lipid synthesis, fatty acid oxidation (FAO), and lipid storage, to survive and proliferate under hypoxic and nutrient-deprived conditions [145]. Besides supporting tumor development, lipid metabolic reprogramming can alter TME properties by affecting the recruitment, activation, and function of immune cells and stromal cells: on one hand, tumor cells actively modify the TME by secreting signaling molecules and metabolites, regulating the functions of CAFs and immune cells

within it [146]; on the other hand, adaptive changes in cellular lipid metabolism within the TME (such as increased lipid uptake and accumulation, enhanced FAO) promote the transformation of the TME towards an immunosuppressive phenotype that supports tumor progression [147]. For example, upregulated lipid uptake and FAO increase lipid metabolic levels in Tregs, TAMs and MDSCs, facilitating their immunosuppressive functions [148-150]. Elevated CD36 expression leads to excessive intracellular lipid accumulation in CD8<sup>+</sup> T cells and NK cells: it inhibits the secretion of anti-tumor factors (IFN- $\gamma$  and TNF- $\alpha$ ) by CD8<sup>+</sup> T cells and impairs the tumor-killing activity of NK cells, respectively [151,152]. Moreover, the metabolic stress field within the TME also exerts a systematic remodeling effect on the activation process, differentiation trajectory, and effector function of immune cells, ultimately resulting in

a significant attenuation of the efficacy of antitumor immune responses [153]. Nutrient competition exists between tumor cells and immune cells: tumor cells consume large amounts of glucose, leading to reduced glucose levels in the TME, limiting glucose uptake and glycolysis in effector T cells, impairing their function, and ultimately leading to exhaustion [154]. Simultaneously, metabolites produced by tumor cells, such as lactate, prostaglandin E2 (PGE2), and fatty acids, also create an immunosuppressive microenvironment [155]. For instance, lactate accumulation induces TME acidification; this acidic environment directly inhibits anti-tumor immune effector cells (like M1 macrophages, T lymphocytes, dendritic cells, NK cells) while enhancing immunosuppressive components (like M2 macrophages, Tregs), thereby promoting tumor immune evasion [156-159].



**Figure 4.** Lipid metabolic reprogramming within the TME driven by metabolic stress. Limitations in glucose and oxygen availability, along with accumulation of lactic acid and lipid peroxidation products, induce adaptive changes in lipid metabolism in both tumor and immune cells, enabling survival and function under nutrient-deprived and acidic conditions [160].

In oxygen-rich zones, tumor cells upregulate VEGF, glucose transporters (GLUT), and monocarboxylate transporter 1 (MCT1), enhancing the Warburg effect and OXPHOS while engaging in partial gluconeogenesis. Acid-sensing receptor OGR1 responds to extracellular H<sup>+</sup>, further modulating metabolic flux. By contrast, in hypoxic regions, tumor cells increase glycolysis, OXPHOS, and the pentose phosphate pathway (PPP), while upregulating MCT4 to export lactate. Hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) promotes fatty acid (FA) uptake via CD36 and induces autophagy, lipogenesis, and cholesterol synthesis to support membrane and energy demands. Concurrently, immune cells such as T cells exhibit reduced lipid droplet degradation and turnover (LDLR), impairing effector functions and antitumor immunity. Elevated lactate and protons in the TME further suppress immune activity


through acid-sensing ion channels and PD-1-mediated exhaustion. FAO and ketone body utilization are enhanced across cell types, providing alternative energy sources and contributing to an overall immunosuppressive, pro-survival metabolic landscape that facilitates tumor progression [160].

### 3.5 Mechanical Stress Response and Adaptive Strategies

The TME contains not only metabolic substances but also various abnormal physical signals, such as the aforementioned increased matrix stiffness, solid stress, fluid stress, and abnormal ECM structure [161]. These biophysical changes affect the metabolic behavior of tumor cells and immune cells, thereby regulating tumor initiation, progression, and therapeutic response (Figure

5). Mechanical signals are sensed by tumor cells through mechanotransduction pathways and elicit responses that ultimately affect their proliferation, migration, invasion, and survival [162]. The concept of "cellular mechanical memory" has been proposed, where cells alter their phenotype in response to a specific physical microenvironment, and this phenotype is retained even after the original physical stimulus is removed and the cells are exposed to a new microenvironment [163]. Solid and fluid stresses can confer mechanical memory to tumor cells, enabling them to acquire biophysical adaptations through responses to high matrix stiffness in the primary TME, and potentially retain these properties via mechanical memory to facilitate metastasis. Primary tumor cells are induced by matrix stiffening and adapt by enhancing proliferation, drug resistance, factor secretion, force generation, altered mechanical properties, and migration [164]. Compared to healthy tissues and even benign tumors, solid malignant tumors (such as breast cancer, pancreatic cancer, liver cancer, prostate cancer) typically exhibit higher stiffness [162,165]. This

characteristic can serve as a diagnostic marker and predictor for cancer risk, survival rate, and recurrence rate [166,167]. In solid tumors, high solid stress affects cell metabolism, gene expression, and the mechanical properties of the ECM [49,168,169]; elevated IFP hinders the delivery of drugs and oxygen to tumor cells, impairs cell migration [168], and is associated with reduced T cell interactions, which may contribute to an immunosuppressive microenvironment [170]. To further construct a microenvironment conducive to tumor growth and therapy escape, tumor cells adaptively secrete various factors to alter the phenotypes of stromal cells, endothelial cells, and immune cells. A typical example is matrix metalloproteinases (MMPs) degrading ECM proteins to promote tumor growth and invasion [171,172]. Furthermore, increased matrix stiffness can directly promote angiogenesis through mechanosensitive pathways involving endothelial cell MMP activity, or indirectly regulate angiogenesis by inducing tumor cells to secrete pro-angiogenic factors like VEGF, thereby affecting endothelial cell behavior [173].



**Figure 5.** Biophysical properties of the TME impair immune cell-cancer cell interactions and promote an immunosuppressive state. Multiple mechanical cues act in concert to limit immune surveillance and support tumor progression. (A) Substrate stiffness influences immune cell function. On soft substrates, T cells exhibit normal migration and tumoricidal activity. In contrast, stiff substrates—often associated with fibrotic tumor stroma—reduce the motility of T cells and specifically impair the effector functions of CD8<sup>+</sup> T cells, thereby weakening anti-tumor immunity. (B) Intratumoral pressure alters immune cell phenotypes. Elevated interstitial pressure within tumors promotes the polarization of macrophages toward a tumor-supportive state, characterized by the secretion of anti-inflammatory cytokines. These cytokines not only inactivate infiltrating effector T cells but also recruit regulatory T cells (Tregs) and other immunosuppressive populations such as MDSCs. The resulting microenvironment favors cancer cell proliferation, limits productive T-cell engagement, and enhances tumor survival. (C) Confined microenvironments limit immune recognition. In densely packed tumor tissue, physical confinement distorts cell shape, disrupts cytoskeletal organization, and reduces the efficiency of antigen uptake and presentation by dendritic cells. Consequently, the chance of successful antigen recognition by T cells is markedly decreased, further compromising adaptive immune responses in the TME. Together, these biophysical barriers—stiffness, pressure, and spatial confinement—cooperatively establish an immune-resistant niche that facilitates tumor evasion and progression [170].

## 4. Therapeutic Strategies Based on Stress Regulation

### 4.1 Therapeutic Strategies Targeting Hypoxic Stress

Current core strategies to improve tumor oxygenation and intervene in hypoxia-related mechanisms are mainly divided into five categories: (1) Improving tumor vascular function: Using vascular normalization agents (such as the VEGF/VEGFR inhibitor bevacizumab) to

optimize tumor vascular structure and function, improving oxygen delivery efficiency [174]. (2) Inhibition of HIF signaling: Directly targeting the HIF pathway involves developing agents that impair the stability or transcriptional activity of HIF-1 $\alpha$  or HIF-2 $\alpha$ . For instance, HIF-prolyl hydroxylase inhibitors (HIF-PHIs) such as roxadustat, which stabilize HIF- $\alpha$  by blocking its degradation, are clinically approved for anemia management. Interestingly, in certain tumor

contexts like glioblastoma, this stabilization can paradoxically induce ferroptosis and suppress growth, revealing a context-dependent therapeutic potential [175]; the HIF-2 $\alpha$  inhibitor Belzutifan has been approved by the US FDA for VHL disease-associated tumors (including renal cell carcinoma, central nervous system hemangioblastoma, pancreatic neuroendocrine tumors) [176]. (3) Utilizing hypoxia-activated prodrugs: Such as tirapazamine (TPZ) and Evofosfamide (TH-302), which are reduced to cytotoxic substances under hypoxic conditions, selectively killing hypoxic tumor cells [177]. (4) Combination therapy to enhance immunotherapy efficacy: Hypoxia impairs immunotherapy efficacy by inhibiting T cell function and promoting immune evasion, which can be reversed by combination strategies, for example, anti-VEGF antibodies (like bevacizumab) combined with PD-1 inhibitors (like pembrolizumab) can remodel the hypoxic and immunosuppressive TME, enhancing immune cell infiltration [178]. (5) Nanomedicine delivery systems: Using oxygen-carrying nanoparticles to directly deliver oxygen to hypoxic regions or as targeted delivery vehicles; for example, manganese dioxide (MnO<sub>2</sub>) NPs can catalytically decompose H<sub>2</sub>O<sub>2</sub> in tumors to produce oxygen in situ, alleviating hypoxia [179]; perfluorocarbon (PFC) nanoemulsions can carry oxygen directly to deep tumor tissues [180]; functionalized superparamagnetic iron oxide NPs (SPIONs) construct intelligent delivery systems co-delivering HIF-1 $\alpha$ /STAT3 siRNA, significantly inhibiting tumor growth in breast and colon cancer models [181]. Nanomedicine delivery systems are constantly being updated and optimized.

#### 4.2 Therapeutic Strategies Targeting Oxidative Stress

Current therapeutic approaches targeting oxidative stress broadly dichotomize into two paradigms: exacerbating ROS accumulation or augmenting ROS clearance. The “ROS overload” strategy exploits the elevated basal ROS levels in cancer cells relative to normal cells. By disabling antioxidant defenses or directly stimulating ROS production, this approach pushes intracellular ROS beyond a tolerable threshold, collapsing redox balance and triggering lethal oxidative damage. Conversely, the “ROS scavenging” paradigm seeks to dampen oncogenic signaling and protect normal tissue by administering antioxidants, deploying enzymatic ROS-neutralizing agents, or inhibiting primary ROS-generating systems.

Regarding the controversial utility of antioxidants in tumor prevention and treatment, current studies show significant divergence: some experiments have confirmed their definite antitumor activity, while others have revealed potential pro-tumor risks, especially with ambiguity in efficacy evaluation when used in combination with chemotherapy. This contradiction may arise from multidimensional variable differences, including the molecular structure type of antioxidants, dosage gradient, intracellular effective concentration distribution, divergent experimental model designs, and heterogeneity in molecular mechanisms of action [6]. Notably, precise regulation of the spatiotemporal distribution of ROS in the TME can specifically enhance the cytotoxic efficacy of CD8<sup>+</sup> T cells and NK cells, and

partially reverse the immunosuppressive microenvironment. However, caution is required regarding the significant heterogeneity in ROS concentration thresholds among different cell subsets: tumor cells may achieve ROS tolerance through antioxidant enzyme systems, whereas immune cells may exhibit dual effects of functional activation and inhibition at specific ROS concentrations. This cell-type-specific difference in ROS sensitivity constitutes a key uncertainty in clinical translational application [26,182]. ROS-targeted therapy combined with nanotechnology can improve drug accumulation in tumors, enhance efficacy, and reduce toxicity; it can also promote ROS generation by releasing oxygen, induce immunogenic cell death, or remodel the TME. This technology platform enables combination therapy (such as depleting GSH, degrading lactate) and synergizes with immune checkpoint blockade (ICB) therapy to enhance anti-PD-L1 efficacy [183]. Although strategies targeting oxidative stress continue to emerge, the high interconnectivity of the ROS regulatory network requires more basic and clinical research to accurately assess the potential of different therapeutic strategies. Nanozymes, as an emerging therapeutic strategy, show great potential in cancer therapy mediated by tumor oxidative stress—due to their enzyme-mimicking activity, low cost, good stability, and large-scale production advantages, they are considered promising substitutes for natural enzymes [184]. For example, multi-enzyme mimetic MoCu dual-atom nanozymes (MoCu DAzyme) can amplify tumor oxidative stress through cascade catalysis to improve efficacy [185]; TME-responsive lipid peroxidation amplifiers (e.g., metal-organic framework (MPN)-coated nanohybrids) can enhance ferroptosis-mediated anti-cancer therapy by scavenging GSH and silencing the glutathione peroxidase 4 (GPX4) gene [186]; another study developed TME-specifically regulated Ca-Fe-nanospheres that synergistically promote ferroptosis and tumor immune responses through calcium overload, ROS-mediated CDT, and SDT [187].

#### 4.3 Therapeutic Strategies Targeting Endoplasmic Reticulum Stress

By intervening in ERS-related pathways, tumor cell death can be induced or anti-tumor immune responses enhanced. Various strategies targeting the UPR pathways have been developed: (1) Targeting the PERK-eIF2 $\alpha$ -ATF4 pathway: ATP-competitive PERK inhibitors (GSK2606414) can block this pathway, increasing the radiosensitivity of breast cancer cells [188]. (2) Targeting the IRE1 $\alpha$ -XBP1 pathway: IRE1 $\alpha$  nuclease inhibitors (MKC-8866) can inhibit IRE1 $\alpha$  nuclease activity, blocking XBP1s production, enhancing the efficacy of chemotherapeutic drugs (like paclitaxel) against triple-negative breast cancer, inducing pyroptosis and inhibiting tumor recurrence [189]; XBP1 splicing inhibitors (STF-083010) can restore the sensitivity of resistant breast cancer cells to endocrine therapy, suggesting the potential application value of XBP1 inhibitors in ER-positive breast cancer [190]. (3) Targeting the glucose-regulated protein 78 (GRP78)

pathway: GRP78 inhibitors (HHQ-4, Plumbagin) can downregulate GRP78 expression, inhibit tumor cell proliferation, and enhance the sensitivity of ER-positive breast cancer to tamoxifen; the phytoestrogen kaempferol can also trigger cell death by inhibiting GRP78-mediated ERS [191]. Additionally, ERS inducers include: Tunicamycins (inducing ERS by inhibiting DPAGT1, a key enzyme in N-glycan biosynthesis, inhibiting tumor cell proliferation, anti-apoptosis, metastasis, and angiogenesis) [192]; Cucurbitacin B (inhibiting glioblastoma via the STAT3/ROS/ERS pathway) [193]; Usenamine A (UD32-3, a natural compound exerting anti-non-small cell lung cancer (NSCLC) activity by inducing ERS and Notch1-mediated autophagy, and enhancing the cytotoxicity of gemcitabine) [194]. Furthermore, ERS-related molecules can also serve as potential therapeutic targets: Glucose-regulated proteins (GRPs, like GRP78, GRP94, GRP96) are upregulated under ERS and play important roles in cancer cell survival, immune evasion, and therapy resistance, serving as vaccine targets [195]; the ORMDL protein family (ORMDL1/2/3) affects cell proliferation, apoptosis, and metabolic balance by regulating sphingolipid metabolism and maintaining ER homeostasis, and their abnormal expression and function in various tumors make them potential therapeutic targets [196]; Luman/CREB3 regulatory factor (CREBRF) participates in ERS and regulates the UPR, leading to the accumulation of misfolded proteins, garnering significant attention in oncology [197]. Combination therapy strategies are also applicable to ERS-targeted therapy: ERS-targeting drugs can remodel the TME, turning "cold" tumors into "hot" tumors, and enhance the efficacy of ICIs [198]. ERS-targeting nanodrugs (like PPRK@MTO) combined with photodynamic therapy can amplify ERS, induce immunogenic cell death, and improve efficacy [199].

#### 4.4 Therapeutic Strategies Targeting Metabolic Stress

Current intervention strategies focus on a system of precision targeting of metabolic nodes, with specific approaches as follows: (1) Targeting glucose metabolism: Glycolytic pathway inhibitors (such as 2-deoxy-D-glucose (2-DG) and dichloroacetate (DCA)) are employed in an energy-deprivation strategy to block the aberrant aerobic glycolysis (Warburg effect) unique to tumor cells, reduce their energy supply, and enhance chemosensitivity [200]; targeting key glycolytic enzymes: a molecular blockade strategy is implemented against core nodal enzymes in the glycolytic pathway, for example, hexokinase 2 (HK2) inhibitor lonidamine [201], the PKM2 inhibitor Shikonin [202], and the LDHA inhibitor FX-11 [203]. These molecules, by specifically binding to enzyme active sites or interfering with enzyme conformation, exhibit significant tumor growth-suppressive activity in preclinical models [204]. (2) Targeting amino acid metabolism: Developing inhibitors targeting key enzymes in amino acid metabolism, such as glutaminase (GLS) inhibitors (like CB-839) [205], arginase inhibitors (like OAT-1746) [206], and indoleamine 2,3-dioxygenase (IDO) inhibitors (like Epcadostat), to interfere with amino acid

utilization by tumor cells and immune cells, thereby regulating the TME [207]. (3) Targeting lipid metabolism: Using fatty acid synthase (FASN) inhibitors (such as TVB-2640) [208], acetyl-CoA carboxylase (ACC) inhibitors (such as ND-646) [209], and fatty acid uptake inhibitors (such as CD36 inhibitors) to disrupt lipid synthesis and uptake in tumor cells, inducing metabolic stress and cell death [210]. (4) Targeting mitochondrial metabolism: Using OXPHOS inhibitors (such as Metformin, IACS-010759) to inhibit the energy metabolism of tumor cells dependent on OXPHOS [211]. (5) Targeting metabolic symbiosis: Disrupting the metabolic symbiosis between tumor cells and stromal cells (such as CAFs), for example, by inhibiting lactate shuttle (using monocarboxylate transporter (MCT) inhibitors like AZD3965) or disrupting glutamine metabolism, to cut off the nutrient supply chain between cells [212]. (6) Targeting metabolic checkpoints in immunotherapy: Combining metabolic modulators with ICIs to improve the efficacy of immunotherapy, for example, using LDHA inhibitors to reduce lactate production, alleviating TME acidification, and restoring T cell function [213]. (7) Nanomedicine-based metabolic intervention: Designing nanocarriers to deliver metabolic inhibitors specifically to tumor tissues, improving drug bioavailability and reducing systemic toxicity, for example, nanoparticles loaded with glycolysis inhibitors can target tumor cells and enhance anti-tumor effects [214]. (8) Dietary intervention: Utilizing specific dietary patterns (such as ketogenic diets, fasting-mimicking diets) to alter systemic metabolism, thereby affecting tumor metabolism and growth, and enhancing the efficacy of conventional therapies [215].

#### 4.5 Therapeutic Strategies Targeting Mechanical Stress

Targeting the mechanical stress of the TME is an emerging field in cancer therapy. By intervening in the mechanical properties of the TME, drug delivery efficiency can be improved, tumor growth and metastasis can be inhibited, and the efficacy of other treatments can be enhanced [211,216]. Current strategies mainly include: (1) Targeting ECM stiffness: It can inhibit ECM synthesis and remodeling by targeting molecules such as LOX, transforming growth factor- $\beta$  (TGF- $\beta$ ) and CD44, degrade core ECM components like hyaluronic acid and collagen, or weaken the supportive effect of CAFs on tumor growth and progression by targeting targets including sonic hedgehog (SHH) and fibroblast activation protein (FAP), thereby disrupting the tumor-supportive microenvironment and restricting tumor growth and invasion [216]. (2) Targeting solid stress: Using angiotensin receptor blockers (ARBs, such as Losartan) to reduce solid stress by inhibiting the renin-angiotensin system (RAS), thereby improving blood perfusion and drug delivery [217]; developing tumor-penetrating peptides (such as iRGD) to enhance drug penetration into tumor tissues [218]. (3) Targeting IFP: Using vascular normalization agents (such as bevacizumab) to reduce IFP by normalizing tumor blood vessels or promoting lymphatic drainage, thereby improving drug delivery [219]. (4) Combination therapy:

Combining mechanical stress-targeting strategies with other treatments (such as chemotherapy, immunotherapy) to achieve synergistic effects; for example, using Losartan combined with chemotherapy or immunotherapy can improve drug delivery and enhance anti-tumor immune responses [220]. Although interventions targeting the mechanical microenvironment are still in the early developmental stage, their translational medical value is particularly remarkable—especially in optimizing drug delivery efficiency and blocking the metastatic pathways of cancer cells. This “mechanical microenvironment regulatory framework” reshapes the mechanical signature of the physical space within tumor tissue. It not only breaches the fibrotic stromal barrier to enable efficient penetration of nanocarriers, but also blocks the “mechanotaxis” machinery that guides cancer cell migration along mechanical gradients by inhibiting mechanosensitive ion channels and integrin signaling pathways, thus achieving a dual synergistic effect of enhanced delivery and suppressed metastasis.

However, critical challenges still exist for clinical translation. There is a need to develop tissue-specific mechanical-targeting carriers to avoid collateral damage to normal tissues. Meanwhile, “spatiotemporal synergistic” strategies with existing regimens such as immunotherapy and targeted therapy should be explored to realize the leap from single-mechanism intervention to multimodal therapy [7,221,222].

## 5. Outlook and Summary

In summary, the TME is a multifaceted ecosystem where tumor, stromal, and immune cells interact under a constellation of stresses—including hypoxia, nutrient lack, oxidative and ER stress, metabolic derangement, and mechanical force. These stresses act as potent drivers of malignancy and architects of therapy resistance by fostering adaptive survival mechanisms. Consequently, therapeutic interception of these stress pathways and their downstream adaptations has emerged as a pivotal frontier in cancer treatment. Current research has made significant progress in targeting various TME stresses, including improving tumor oxygenation, regulating redox balance, inducing endoplasmic reticulum stress, intervening in metabolic pathways, and modulating mechanical properties. These strategies have shown promising results in preclinical studies and some clinical trials. However, challenges remain, such as the complexity and plasticity of the TME, the potential side effects of targeted therapies, and the need for effective combination strategies.

This review synthesizes recent advances in understanding how interconnected stress pathways in the TME, cooperatively drive tumor progression and immune evasion. We highlight the novel concept of “stress induction–immune activation” as a dual-targeting strategy to overcome therapy resistance. Unlike previous reviews focusing on single stress types, this work provides an integrated perspective on the crosstalk between different stress responses and their collective impact on the TME.

Future investigations should prioritize the following directions: First, elucidating the interactive networks and integrated effects of different stress signals within the tumor microenvironment, in order to uncover the systemic principles through which they collectively drive tumor progression and therapy resistance. Second, developing targeted drugs or interventions with greater specificity and efficacy, thereby minimizing off-target effects on normal tissues. Third, exploring optimized combination strategies that integrate stress-targeting therapies with immunotherapy, chemotherapy, or radiotherapy to achieve synergistic antitumor outcomes. Fourth, leveraging cutting-edge technologies – including nanomedicine, artificial intelligence, and advanced imaging—to enhance drug delivery, dynamically monitor treatment responses, and guide personalized therapeutic regimens. Moving forward, several concrete pathways can be pursued: establishing integrated multi-omics platforms to systematically map stress-pathway interactions in patient tumors; designing intelligent nanocarriers capable of sequentially targeting multiple TME stressors; and launching clinical trials that evaluate the synergistic potential of combining mechanical modulators (e.g., Losartan) with immune-checkpoint inhibitors. These efforts will help translate mechanistic insights into clinically effective, precision-based combination therapies.

In conclusion, the strategic targeting of TME-associated stresses and the adaptive programs they engage presents a highly promising avenue for overcoming therapeutic resistance. As research uncovers deeper mechanistic insights and technologies for precise intervention advance, the development of more effective and tailored combination therapies is anticipated, offering renewed hope for improving outcomes in cancer patients.

## Abbreviations

ACC: Acetyl-CoA carboxylase

ANG: Angiotensin II

ARG1: Arginine via arginase 1

ATF6: Activating transcription factor 6

CAFs: Cancer-associated fibroblasts

CAT: Catalase

CREBRF: CREB3 regulatory factor

DCA: Dichloroacetate

DCs: Dendritic cells

ECM: Extracellular matrix

EGFR: Epidermal growth factor receptor

eIF2 $\alpha$ : Eukaryotic initiation factor 2 $\alpha$

EMT: Epithelial-mesenchymal transition

EPO: Erythropoietin

ER: Endoplasmic reticulum

ERAD: ER-associated degradation

EVs: Extracellular vesicles  
 FA: Fatty acid  
 FAO: Fatty acid oxidation  
 FAP: Fibroblast activation protein  
 FASN: Fatty acid synthase  
 GAMs: Glioma-associated microglia/macrophages  
 GLS: Glutaminase  
 GLUT: Glucose transporters  
 GPx: Glutathione peroxidase  
 GPX4: Glutathione peroxidase 4  
 GRP78: Glucose-regulated protein 78  
 GSH: Glutathione  
 HIF: Hypoxia-inducible factor  
 HIF-1 $\alpha$ : Hypoxia-inducible factor-1 $\alpha$   
 HIFs: Hypoxia-inducible factors  
 hiTDExs: Hypoxia-induced tumor-derived exosomes  
 HK2: Hexokinase 2  
 HREs: Hypoxia response elements  
 HSP47: Heat shock protein 47  
 ICB: Immune checkpoint blockade  
 ICIs: Immune checkpoint inhibitors  
 ICPs: Immune checkpoint proteins  
 IFP: Interstitial fluid pressure  
 IL-1A: Interleukin-1A  
 IRE1 $\alpha$ : Inositol-requiring enzyme 1 $\alpha$   
 IRS-1: Insulin receptor substrate 1  
 JAK: Janus kinase  
 LDDR: Lipid droplet degradation and turnover  
 LOX: Lysyl oxidase  
 MCT: Monocarboxylate transporter  
 MCT1: Monocarboxylate transporter 1  
 MDSCs: Myeloid-derived suppressor cells  
 MMPs: Matrix metalloproteinases  
 mtDNA: Mitochondrial DNA  
 NK: Natural killer  
 NRF2: Nuclear factor erythroid 2-related factor 2  
 NSCLC: Non-small cell lung cancer  
 OSCC: Oral squamous cell carcinoma  
 OXPHOS: Oxidative phosphorylation  
 PDK1: Phosphoinositide-dependent protein kinase 1  
 PERK: PKR-like ER kinase

PFC: Perfluorocarbon  
 PGE2: Prostaglandin E2  
 PI3K: Phosphatidylinositol 3-kinase  
 PPP: Pentose phosphate pathway  
 PTP: Protein tyrosine phosphatase  
 PTP1B: Protein tyrosine phosphatase 1B  
 ROS: Reactive oxygen species  
 SHH: Sonic hedgehog  
 SOD: Superoxide dismutase  
 SPIONs: Superparamagnetic iron oxide NPs  
 STAT3: Signal transducer and activator of transcription 3  
 TCR: T-cell receptor  
 TH-302: Evofosfamide  
 TME: Tumor microenvironment  
 TPZ: Tirapazamine  
 UPR: Unfolded protein response  
 XBP1: X-box binding protein 1

### Conflict of Interest

All authors declared there is no conflict of interest in this work.

### Generative AI Statement

The authors declare that no generative artificial intelligence technologies were used in the preparation of this manuscript.

### References

- [1] Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. *Cancer Medicine*. 2023, 12(10), 11149-11165. DOI: 10.1002/cam4.5698
- [2] Wu YZ, Su YH, Kuo CY. Stressing the regulatory role of long non-coding RNA in the cellular stress response during cancer progression and therapy. *Biomedicine*. 2022, 10(5), 1212. DOI: 10.3390/biomedicine10051212
- [3] de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. *Cancer Cell*. 2023, 41(3), 374-403. DOI: 10.1016/j.ccell.2023.02.016
- [4] Goliwas KF, Deshane JS, Elmets CA, Athar M. Moving immune therapy forward targeting TME. *Physiological Reviews*. 2021, 101(2), 417-425. DOI: 10.1152/physrev.00008.2020
- [5] Devi D, Sharma K, Khan T, Rani H, Rana R, Sharma H, et al. Hypoxia-driven metabolic and molecular reprogramming: from tumor microenvironment to therapeutic interventions. *Pathology, Research and Practice*. 2025, 276, 156271. DOI: 10.1016/j.prp.2025.156271
- [6] Liang X, Weng J, You Z, Wang Y, Wen J, Xia Z, et al. Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers. *Molecular Cancer*. 2025, 24(1), 219. DOI:

- 10.1186/s12943-025-02375-x
- [7] Kalli M, Stylianopoulos T. Toward innovative approaches for exploring the mechanically regulated tumor-immune microenvironment. *APL Bioengineering*. 2024, 8(1), 011501. DOI: 10.1063/5.0183302
- [8] Wang DW. Analysis on endoplasmic reticulum stress in the cancer cells. *Theoretical and Natural Science*. 2023, 22(1), 17-24. DOI: 10.54254/2753-8818/22/20230912
- [9] Liang XH, Chen XY, Yan Y, Cheng AY, Lin JY, Jiang YX, et al. Targeting metabolism to enhance immunotherapy within tumor microenvironment. *Acta Pharmacologica Sinica*. 2024, 45(10), 2011-2022. DOI: 10.1038/s41401-024-01304-w
- [10] Shah DD, Chorawala MR, Raghani NR, Patel R, Fareed M, Kashid VA, et al. Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies. *Medical Oncology*. 2025, 42(4), 117. DOI: 10.1007/s12032-025-02641-4
- [11] Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. *Technology in Cancer Research & Treatment*. 2021, 20, 15330338211036304. DOI: 10.1177/15330338211036304
- [12] Grasmann G, Mondal A, Leithner K. Flexibility and adaptation of cancer cells in a heterogenous metabolic microenvironment. *International Journal of Molecular Sciences*. 2021, 22(3), 1476. DOI: 10.3390/ijms22031476
- [13] Attique I, Haider Z, Khan M, Hassan S, Soliman MM, Ibrahim WN, et al. Reactive oxygen species: from tumorigenesis to therapeutic strategies in cancer. *Cancer Medicine*. 2025, 14(10), e70947. DOI: 10.1002/cam4.70947
- [14] Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. *International Journal of Molecular Sciences*. 2020, 21(21), 8363. DOI: 10.3390/ijms21218363
- [15] Salavati H, Debbaut C, Pullens P, Ceelen W. Interstitial fluid pressure as an emerging biomarker in solid tumors. *Biochimica et Biophysica Acta. Reviews on Cancer*. 2022, 1877(5), 188792. DOI: 10.1016/j.bbcan.2022.188792
- [16] Wang L, Zhang L, Zhang Z, Wu P, Zhang Y, Chen X. Advances in targeting tumor microenvironment for immunotherapy. *Frontiers in Immunology*. 2024, 15, 1472772. DOI: 10.3389/fimmu.2024.1472772
- [17] Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. *Signal Transduction and Targeted Therapy*. 2023, 8(1), 70. DOI: 10.1038/s41392-023-01332-8
- [18] Sun Y, Chen W, Torphy RJ, Yao S, Zhu G, Lin R, et al. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. *Science Translational Medicine*. 2021, 13(604), eabc8922. DOI: 10.1126/scitranslmed.abc8922
- [19] Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. *Nature Reviews. Clinical Oncology*. 2021, 18(12), 751-772. DOI: 10.1038/s41571-021-00539-4
- [20] Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. *Nature Reviews. Cancer*. 2014, 14(6), 430-9. DOI: 10.1038/nrc3726
- [21] Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. *Journal of Cellular and Molecular Medicine*. 2013, 17(1), 30-54. DOI: 10.1111/jcmm.12004
- [22] De Miguel MP, Alcaina Y, de la Maza DS, Lopez-Iglesias P. Cell metabolism under microenvironmental low oxygen tension levels in stemness, proliferation and pluripotency. *Current Molecular Medicine*. 2015, 15(4), 343-59. DOI: 10.2174/1566524015666150505160406
- [23] Shi R, Liao C, Zhang Q. Hypoxia-driven effects in cancer: characterization, mechanisms, and therapeutic implications. *Cells*. 2021, 10(3), 678. DOI: 10.3390/cells10030678
- [24] Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA. Hypoxic regulation of metastasis via hypoxia-inducible factors. *Current Molecular Medicine*. 2008, 8(1), 60-7. DOI: 10.2174/156652408783565568
- [25] Chang J, Erler J. Hypoxia-mediated metastasis. *Advances in Experimental Medicine and Biology*. 2014, 772, 55-81. DOI: 10.1007/978-1-4614-5915-6\_3
- [26] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: The metabolic requirements of cell proliferation. *Science*. 2009, 324(5930), 1029-33. DOI: 10.1126/science.1160809
- [27] Keating ST, El-Osta A. Metaboloepigenetics in cancer, immunity and cardiovascular disease. *Cardiovascular Research*. 2023, 119(2), 357-370. DOI: 10.1093/cvr/cvac058
- [28] Adighibe O, Leek RD, Fernandez-Mercado M, Hu J, Snell C, Gatter KC, et al. Why some tumours trigger neovascularisation and others don't: the story thus far. *Chinese Journal of Cancer*. 2016, 35, 18. DOI: 10.1186/s40880-016-0082-6
- [29] Yashiro N, Takai M, Yamamoto M, Kusumoto Y, Nagano S, Taniguchi A, et al. Cellular responses to low nutrient conditions via activation of lysophosphatidic acid (LPA) receptor signaling in gastric cancer cells. *Advances in Biological Regulation*. 2025, 96, 101068. DOI: 10.1016/j.jbior.2024.101068
- [30] Yang P, Zhang J. Indoleamine 2,3-dioxygenase (IDO) activity: a perspective biomarker for laboratory determination in tumor immunotherapy. *Biomedicines*. 2023, 11(7), 1988. DOI: 10.3390/biomedicines11071988
- [31] Karadima E, Chavakis T, Alexaki VI. Arginine metabolism in myeloid cells in health and disease. *Seminars in Immunopathology*. 2025, 47(1), 11. DOI: 10.1007/s00281-025-01038-9
- [32] Ling ZN, Jiang YF, Ru JN, Lu JH, Ding B, Wu J. Amino acid metabolism in health and disease. *Signal Transduction and Targeted Therapy*. 2023, 8(1), 345. DOI: 10.1038/s41392-023-01569-3
- [33] Yao S, Chai H, Tao T, Zhang L, Yang X, Li X, et al. Role of lactate and lactate metabolism in liver diseases (review). *International Journal of Molecular Medicine*. 2024, 54(1), 59. DOI: 10.3892/ijmm.2024.5383
- [34] Rastogi S, Mishra SS, Arora MK, Kaithwas G, Banerjee S, Ravichandiran V, et al. Lactate acidosis and simultaneous recruitment of TGF- $\beta$  leads to alter plasticity of hypoxic cancer cells in tumor microenvironment. *Pharmacology & Therapeutics*. 2023, 250, 108519. DOI: 10.1016/j.pharmthera.2023.108519
- [35] Liu Y, Si L, Jiang Y, Jiang S, Zhang X, Li S, et al. Design of pH-responsive nanomaterials based on the tumor microenvironment. *International Journal of Nanomedicine*. 2025, 20, 705-721. DOI: 10.2147/ijn.s504629
- [36] Dubuisson A, Mangelinck A, Knockaert S, Zichi A, Becht E, Philippon W, et al. Glucose deprivation and identification of TXNIP as an immunometabolic modulator of T cell activation in cancer. *Frontiers in Immunology*. 2025, 16, 1548509. DOI: 10.3389/fimmu.2025.1548509
- [37] Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. *Experimental & Molecular Medicine*. 2020, 52(2), 192-203. DOI: 10.1038/s12276-020-0384-2

- [38] Imai H. [biological significance of lipid hydroperoxide and its reducing enzyme, phospholipid hydroperoxide glutathione peroxidase, in mammalian cells]. *Yakugaku Zasshi*. 2004, 124(12), 937-57. DOI: 10.1248/yakushi.124.937
- [39] Ramalingam V, Rajaram R. A paradoxical role of reactive oxygen species in cancer signaling pathway: physiology and pathology. *Process Biochemistry*. 2021, 100, 69-81. DOI: 10.1016/j.procbio.2020.09.032
- [40] Zhao Y, Ye X, Xiong Z, Ihsan A, Ares I, Martínez M, et al. Cancer metabolism: the role of ROS in DNA damage and induction of apoptosis in cancer cells. *Metabolites*. 2023, 13(7), 796. DOI: 10.3390/metabo13070796
- [41] Lisanti MP, Martínez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, et al. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs “fertilizer”. *Cell Cycle*. 2011, 10(15), 2440-9. DOI: 10.4161/cc.10.15.16870
- [42] Hao S, Cai D, Gou S, Li Y, Liu L, Tang X, et al. Does each component of reactive oxygen species have a dual role in the tumor microenvironment? *Current Medicinal Chemistry*. 2024, 31(31), 4958-4986. DOI: 10.2174/0929867331666230719142202
- [43] Nakamura H, Takada K. Reactive oxygen species in cancer: current findings and future directions. *Cancer Science*. 2021, 112(10), 3945-3952. DOI: 10.1111/cas.15068
- [44] Tian Y, Tang L, Wang X, Ji Y, Tu Y. Nrf2 in human cancers: biological significance and therapeutic potential. *American Journal of Cancer Research*. 2024, 14(8), 3935-3961. DOI: 10.62347/lzvo6743
- [45] Jomova K, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, Valko M. Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. *Archives of Toxicology*. 2024, 98(5), 1323-1367. DOI: 10.1007/s00204-024-03696-4
- [46] Verma P, Rishi B, George NG, Kushwaha N, Dhandha H, Kaur M, et al. Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment. *Pathology Oncology Research*. 2023, 29, 1611415. DOI: 10.3389/pore.2023.1611415
- [47] Northey JJ, Przybyla L, Weaver VM. Tissue force programs cell fate and tumor aggression. *Cancer Discovery*. 2017, 7(11), 1224-1237. DOI: 10.1158/2159-8290.cd-16-0733
- [48] Yan H, Ramirez-Guerrero D, Lowengrub J, Wu M. Stress generation, relaxation and size control in confined tumor growth. *PLoS Computational Biology*. 2021, 17(12), e1009701. DOI: 10.1371/journal.pcbi.1009701
- [49] Purkayastha P, Jaiswal MK, Lele TP. Molecular cancer cell responses to solid compressive stress and interstitial fluid pressure. *Cytoskeleton*. 2021, 78(6), 312-322. DOI: 10.1002/cm.21680
- [50] Dwairy M, Reddy JN, Righetti R. Predicting stress and interstitial fluid pressure in tumors based on biphasic theory. *Computers in Biology and Medicine*. 2023, 167, 107651. DOI: 10.1016/j.combiomed.2023.107651
- [51] Cuesta C, Alcon M, Zheng J, Prócel N, Cota RR, Fennema D, et al. RAS-PI3K pathway in CAFs shapes physicochemical properties of tumor ECM to impact tumor progression. *Biorxiv-Cancer Biology*. 2025. DOI: 10.1101/2025.01.20.633776
- [52] Peng Z, Ding YL, Zhang HY, Meng X, Huang YY, Zhang PF, et al. Mechanical force-mediated interactions between cancer cells and fibroblasts and their role in the progression of hepatocellular carcinoma. *Journal of Cancer Metastasis and Treatment*. 2024, 10, 4. DOI: 10.20517/2394-4722.2023.137
- [53] Ye M, Song Y, Pan S, Chu M, Wang ZW, Zhu X. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy. *Pharmacology & Therapeutics*. 2020, 215, 107633. DOI: 10.1016/j.pharmthera.2020.107633
- [54] Ansardamavandi A, Tafazzoli-Shadpour M. The functional cross talk between cancer cells and cancer associated fibroblasts from a cancer mechanics perspective. *Biochimica et Biophysica Acta. Molecular Cell Research*. 2021, 1868(11), 119103. DOI: 10.1016/j.bbamcr.2021.119103
- [55] Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. *Signal Transduction and Targeted Therapy*. 2021, 6(1), 153. DOI: 10.1038/s41392-021-00544-0
- [56] Heydari S, Tajik F, Safaei S, Kamani F, Karami B, Dorafshan S, et al. The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review. *Breast Cancer Research*. 2025, 27(1), 69. DOI: 10.1186/s13058-025-02017-6
- [57] Li P, Zhou H, Yan R, Yan W, Yang L, Li T, et al. Aligned fibrous scaffolds promote directional migration of breast cancer cells via caveolin-1/YAP-mediated mechanosensing. *Materials Today. Bio*. 2024, 28, 101245. DOI: 10.1016/j.mtbio.2024.101245
- [58] Keller SB, Averkiou MA. The role of ultrasound in modulating interstitial fluid pressure in solid tumors for improved drug delivery. *Bioconjugate Chemistry*. 2022, 33(6), 1049-1056. DOI: 10.1021/acs.bioconjchem.1c00422
- [59] He YQ, Yang MX, Wang T, Xu LY, Ma ZH, Mu J, et al. Regulation of interstitial fluid pressure for improved intratumor drug permeability and nanozyme-enhanced chemocatalytic therapy. *ACS Sustainable Chemistry & Engineering*. 2022, 10(27), 8908-8918. DOI: 10.1021/acssuschemeng.2c02129
- [60] Li H, Jin W, Liu J, Zhou Y, Shan X, Zhang Y, et al. Optimizing mitochondria function in immune cells: implications for cancer immunotherapy. *Trends in Cancer*. 2025, 11(12), 1170-1184. DOI: 10.1016/j.trecan.2025.08.006
- [61] Lv Y, Lv Y, Wang Z, Yuan K, Zeng Y. Noncoding RNAs as sensors of tumor microenvironmental stress. *Journal of Experimental & Clinical Cancer Research*. 2022, 41(1), 224. DOI: 10.1186/s13046-022-02433-y
- [62] Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. *Cancer Cell*. 2020, 38(2), 167-197. DOI: 10.1016/j.ccell.2020.06.001
- [63] Skrabalak I, Rajtak A, Malachowska B, Skrzypczak N, Skalina KA, Guha C, et al. Therapy resistance: modulating evolutionarily conserved heat shock protein machinery in cancer. *Cancer Letters*. 2025, 616, 217571. DOI: 10.1016/j.canlet.2025.217571
- [64] Hahne M, Schumann P, Mursell M, Strehl C, Hoff P, Buttgerit F, et al. Unraveling the role of hypoxia-inducible factor (HIF)-1 $\alpha$  and HIF-2 $\alpha$  in the adaptation process of human microvascular endothelial cells (HMEC-1) to hypoxia: redundant HIF-dependent regulation of macrophage migration inhibitory factor. *Microvascular Research*. 2018, 116, 34-44. DOI: 10.1016/j.mvr.2017.09.004
- [65] Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O<sub>2</sub> tension. *Proceedings of the National Academy of Sciences of the United States of America*. 1995, 92(12), 5510-4. DOI: 10.1073/pnas.92.12.5510

- [66] Chowdhury M, Das PK. Hypoxia: intriguing feature in cancer cell biology. *ChemMedChem*. 2024, 19(9), e202300551. DOI: 10.1002/cmde.202300551
- [67] Shi S, Ou X, Liu C, Wen H, Ke J. Research progress of HIF-1 $\alpha$  on immunotherapy outcomes in immune vascular microenvironment. *Frontiers in Immunology*. 2025, 16, 1549276. DOI: 10.3389/fimmu.2025.1549276
- [68] Jin F, Zheng X, Yang Y, Yao G, Ye L, Doeppner TR, et al. Impairment of hypoxia-induced angiogenesis by LDL involves a HIF-centered signaling network linking inflammatory TNF $\alpha$  and angiogenic VEGF. *Aging-Us*. 2019, 11(2), 328-349. DOI: 10.18632/aging.101726
- [69] Ha H, Choi Y, Kim NH, Kim J, Jang J, Niepa THR, et al. Lipid nanoparticle delivery system for normalization of tumor microenvironment and tumor vascular structure. *Biomaterials Research*. 2025, 29, 0144. DOI: 10.34133/bmr.0144
- [70] Guan Y, Weeder B, Patnaik A, Ornstein M, Garmezy B, Drakaki A, et al. Abstract A023: erythropoietin (EPO) is a pharmacodynamic biomarker for systemic HIF-2 $\alpha$  inhibition that correlates with the clinical activity of casdatifan. *Molecular Cancer Therapeutics*. 2025, 24(10), A023-A023. DOI: 10.1158/1535-7163.targ-25-a023
- [71] Lin S, Chai Y, Zheng X, Xu X. The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers. *Molecular Biology Reports*. 2023, 51(1), 14. DOI: 10.1007/s11033-023-08931-2
- [72] Zhang J, Yao M, Xia S, Zeng F, Liu Q. Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. *Cellular & Molecular Biology Letters*. 2025, 30(1), 2. DOI: 10.1186/s11658-024-00682-7
- [73] Juhász P, Méhes G. Tumor hypoxia: how conventional histology is reshaped in breast carcinoma. *International Journal of Molecular Sciences*. 2025, 26(9), 4423. DOI: 10.3390/ijms26094423
- [74] Zaarour RF, Ribeiro M, Azzarone B, Kapoor S, Chouaib S. Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance. *Frontiers in Oncology*. 2023, 13, 1222575. DOI: 10.3389/fonc.2023.1222575
- [75] Owida HA, Saleh RO, Mohammad SI, Vasudevan A, Roopashree R, Kashyap A, et al. Deciphering the role of circular RNAs in cancer progression under hypoxic conditions. *Medical Oncology*. 2025, 42(6), 191. DOI: 10.1007/s12032-025-02727-z
- [76] Capik O, Karatas OF. Pathways and outputs orchestrated in tumor microenvironment cells by hypoxia-induced tumor-derived exosomes in pan-cancer. *Cellular Oncology*. 2025, 48(3), 539-557. DOI: 10.1007/s13402-025-01042-z
- [77] Wu Z, Fang ZX, Hou YY, Wu BX, Deng Y, Wu HT, et al. Exosomes in metastasis of colorectal cancers: friends or foes?. *World Journal of Gastrointestinal Oncology*. 2023, 15(5), 731-756. DOI: 10.4251/wjgo.v15.i5.731
- [78] Wang CR, Xu S, Yang X. Hypoxia-driven changes in tumor microenvironment: insights into exosome-mediated cell interactions. *International Journal of Nanomedicine*. 2024, 19, 8211-8236. DOI: 10.2147/ijn.s479533
- [79] Abou Khouzam R, Janji B, Thiery J, Zaarour RF, Chamseddine AN, Mayr H, et al. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: impact on cancer immunotherapy. *Seminars in Cancer Biology*. 2023, 97, 104-123. DOI: 10.1016/j.semcan.2023.11.008
- [80] Ciepla J, Smolarczyk R. Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies. *Clinical and Experimental Medicine*. 2024, 24(1), 235. DOI: 10.1007/s10238-024-01501-1
- [81] Garemilla SSS, Gampa SC, Garimella S. Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance. *Medical Oncology*. 2025, 42(6), 202. DOI: 10.1007/s12032-025-02754-w
- [82] Alexandra Meyer, Luke Riggan. Mechanisms behind hypoxia-driven resistance to immunotherapy in the tumor microenvironment. *Journal of Student Research*. 2022, 11(3). DOI: 10.47611/jsrhs.v11i3.3837
- [83] Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. *Nature Reviews Cancer*. 2024, 25(1), 41-58. DOI: 10.1038/s41568-024-00761-z
- [84] Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. *Life Sciences*. 2021, 286, 120057. DOI: 10.1016/j.lfs.2021.120057
- [85] Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. *Journal of Cellular Biochemistry*. 2019, 120(3), 2782-2790. DOI: 10.1002/jcb.27681
- [86] Retamal MA, Salazar-Onfray F, González FE, Tittarelli A. Tumor hypoxia shapes natural killer cell anticancer activities. *Journal of Molecular Medicine*. 2025, 103(7), 755-777. DOI: 10.1007/s00109-025-02557-6
- [87] Kim I, Choi S, Yoo S, Lee M, Kim IS. Cancer-associated fibroblasts in the hypoxic tumor microenvironment. *Cancers*. 2022, 14(14), 3321. DOI: 10.3390/cancers14143321
- [88] Dzwigonska M, Rosa P, Lipiec S, Obrebski T, Smyk G, Kaza B, et al. Hypoxic stress dysregulates functions of glioma-associated myeloid cells through epigenomic and transcriptional programs. *Cell Reports*. 2025, 44(9), 116222. DOI: 10.1016/j.celrep.2025.116222
- [89] Glorieux C, Liu SH, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. *Nature Reviews. Drug Discovery*. 2024, 23(8), 583-606. DOI: 10.1038/s41573-024-00979-4
- [90] Cheung EC, Vousden KH. The role of ROS in tumour development and progression. *Nature Reviews. Cancer*. 2022, 22(5), 280-297. DOI: 10.1038/s41568-021-00435-0
- [91] Aboelella NS, Brandle C, Kim T, Ding ZC, Zhou G. Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy. *Cancers*. 2021, 13(5), 986. DOI: 10.3390/cancers13050986
- [92] Wu CC, Mao YT, Wang X, Li P, Tang B. Deep-tissue fluorescence imaging study of reactive oxygen species in a tumor microenvironment. *Analytical Chemistry*. 2022, 94(1), 165-176. DOI: 10.1021/acs.analchem.1c03104
- [93] Jin P, Feng XD, Huang CS, Li J, Wang H, Wang XM, et al. Oxidative stress and cellular senescence: Roles in tumor progression and therapeutic opportunities. *Medcomm-Oncology*. 2024. DOI: 10.1002/mog2.70007
- [94] Kuo CL, Ponneri Babuharisankar A, Lin YC, Lien HW, Lo YK, Chou HY, et al. Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?. *Journal of Biomedical Science*. 2022, 29(1), 74. DOI: 10.1186/s12929-022-00859-2
- [95] D'Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. *Nature Reviews Molecular Cell Biology*. 2007, 8(13), 813-824. DOI: 10.1038/nrm2256
- [96] González-Pacheco FR, Caramelo C, Castilla MA, Deudero JJ, Arias J, Yagüe S, et al. Mechanism of vascular smooth muscle cells activation by hydrogen peroxide: Role of phospholipase C gamma. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*. 2002, 17(3), 392-398. DOI:

- 10.1093/ndt/17.3.392
- [97] Kma L, Baruah TJ. The interplay of ROS and the PI3K/akt pathway in autophagy regulation. *Biotechnol. Biotechnology and Applied Biochemistry*. 2022, 69(1), 248-264. DOI: 10.1002/bab.2104
- [98] Koundouros N, Poulogiannis G. Phosphoinositide 3-kinase/akt signaling and redox metabolism in cancer - PubMed. *Frontiers in Oncology*. 2018, 8, 160. DOI: 10.3389/fonc.2018.00160
- [99] Moloney JN, Cotter TG. ROS signalling in the biology of cancer. *Seminars in Cell & Developmental Biology*. 2018, 80, 50-64. DOI: 10.1016/j.semcdb.2017.05.023
- [100] Iqbal MJ, Kabeer A, Abbas Z, Siddiqui HA, Calina D, Sharifi-Rad J, et al. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. *Cell Communication and Signaling: CCS*. 2024, 22(1), 7. DOI: 10.1186/s12964-023-01398-5
- [101] Stieg DC, Wang Y, Liu LZ, Jiang BH. ROS and miRNA dysregulation in ovarian cancer development, angiogenesis and therapeutic resistance. *International Journal of Molecular Sciences*. 2022, 23(12), 6702. DOI: 10.3390/ijms23126702
- [102] Forman HJ, Zhang HQ, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. *Molecular Aspects of Medicine*. 2009, 30(1-2), 1-12. DOI: 10.1016/j.mam.2008.08.006.
- [103] Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. *Nature Medicine*. 2005, 11(12), 1306-1313. DOI: 10.1038/nm1320
- [104] Teli A, Kshirsagar D, Doshi S, Dey T. Role-of-macrophages-in-oxidative-stress-induced-inflammatory-tumor-microenvironment. *Handbook of Oxidative Stress in Cancer: Mechanistic Aspects*. 2021, 1-16. DOI: 10.1007/978-981-15-4501-6\_61-1
- [105] Wang MM, Xiao YP, Miao J, Zhang X, Liu M, Zhu LC, et al. Oxidative stress and inflammation drivers of tumorigenesis and therapeutic opportunities. *Antioxidants*. 2025, 14(6), 735. DOI: 10.3390/antiox14060735
- [106] Tunio SR, Siyal K, Menghwar K, Memon M, Tunio H, Memon MA. Potential interaction between inflammation and tumor microenvironment. *International Journal of Agriculture and Biology*. 2024, 33(330109), 1-13. DOI: 10.17957/ijab/15.2255
- [107] Ramundo V, Zanirato G, Palazzo ML, Riganti C, Aldieri E. APE-1/ref-1 inhibition blocks malignant pleural mesothelioma cell proliferation and migration: crosstalk between oxidative stress and epithelial mesenchymal transition (EMT) in driving carcinogenesis and metastasis. *International Journal of Molecular Sciences*. 2023, 24(16), 12570. DOI: 10.3390/ijms241612570
- [108] Zou WP. Abstract syl7-01: metabolic impact on immune cell subsets in the tumor microenvironment and its therapeutic relevance. *Tumor Biology*. 2018, 78(13). DOI: 10.1158/1538-7445.am2018-syl7-01
- [109] Weinberg F, Ramnath N, Nagrath D. Reactive oxygen species in the tumor microenvironment: an overview. *Cancers*. 2019, 11(8), 1191. DOI: 10.3390/cancers11081191
- [110] Groenendyk J, Michalak M. Endoplasmic reticulum quality control and apoptosis. *Acta Biochimica Polonica*. 2005, 52(2), 381-395. DOI: 10.18388/abp.2005\_3451
- [111] Zhang DH, Lin LL, Jin H, Mao HJ, Wang LY, Ma WW, et al. Endoplasmic reticulum stress in lung cancer. *Frontiers in Oncology*. 2025, 15, 1550075. DOI: 10.3389/fonc.2025.1550075
- [112] Lu S, Zhou QM, Zhao RJ, Xie L, Cao WM, Feng YX. Unraveling UPR-mediated intercellular crosstalk: implications for immunotherapy resistance mechanisms. *Cancer Letters*. 2025, 617, 217613. DOI: 10.1016/j.canlet.2025.217613
- [113] Peng CS, Wang J, Wang S, Zhao Y, Wang HY, Wang YH, et al. Endoplasmic reticulum stress: triggers microenvironmental regulation and drives tumor evolution. *Cancer Medicine*. 2025, 14(5), e70684. DOI: 10.1002/cam4.70684
- [114] Zarrella S, Miranda MR, Covelli V, Restivo I, Novi S, Pepe G, et al. Endoplasmic reticulum stress and its role in metabolic reprogramming of cancer. *Metabolites*. 2025, 15(4), 221. DOI: 10.3390/metabo15040221
- [115] Wiseman RL, Mesgarzadeh JS, Hendershot LM. Reshaping endoplasmic reticulum quality control through the unfolded protein response. *Molecular Cell*. 2022, 82(8), 1477-1491. DOI: 10.1016/j.molcel.2022.03.025
- [116] Salvagno C, Mandula JK, Rodriguez PC, Cubillos-Ruiz JR. Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. *Trends in Cancer*. 2022, 8(11), 930-943. DOI: 10.1016/j.trecan.2022.06.006
- [117] Panda SK, Sanchez-Pajares IR, Rehman A, Del Vecchio V, Mele L, Chipurupalli S, et al. ER stress and/or ER-phagy in drug resistance? Three coincidences are proof. *Cell Communication and Signaling: CCS*. 2025, 23(1). DOI: 10.1186/s12964-025-02232-w
- [118] Zhang XH, Ma HJ, Gao Y, Liang YB, Du YT, Hao SL, et al. The tumor microenvironment: signal transduction. *Biomolecules*. 2024, 14(4), 438. DOI: 10.3390/biom14040438
- [119] Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. *Nature Reviews. Cancer*. 2021, 21(2), 71-88. DOI: 10.1038/s41568-020-00312-2.
- [120] Lindholm D, Korhonen L, Eriksson O, Kōks S. Recent insights into the role of unfolded protein response in ER stress in health and disease. *Frontiers in Cell and Developmental Biology*. 2017, 5, 48. DOI: 10.3389/fcell.2017.00048
- [121] Puente-Cobacho B, Varela-López A, Quiles JL, Vera-Ramirez L. Involvement of redox signalling in tumour cell dormancy and metastasis. *Cancer Metastasis Reviews*. 2023, 42(1), 49-85. DOI: 10.1007/s10555-022-10077-9
- [122] Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. *Molecular Biology of the Cell*. 1999, 10(11), 3787-3799. DOI: 10.1091/mbc.10.11.3787
- [123] Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T, et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. *Genes & Development*. 2002, 16(4), 452-466. DOI: 10.1101/gad.964702
- [124] Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. *Molecular and Cellular Biology*. 2003, 23(21), 7448-7459. DOI: 10.1128/mcb.23.21.7448-7459.2003
- [125] Gothland A, Jary A, Grange P, Leducq V, Beauvais-Remigereau L, Dupin N, et al. Harnessing redox disruption to treat human herpesvirus 8 (HHV-8) related malignancies. *Antioxidants*. 2022, 12(1), 84. DOI: 10.3390/antiox12010084
- [126] Zhang WL, Shi YD, Oyang LD, Cui SW, Li SZ, Li JY, et al. Endoplasmic reticulum stress-a key guardian in cancer. *Cell Death Discovery*. 2024, 10(1), 343. DOI: 10.1038/s41420-024-02110-3
- [127] Vera-Ramirez L, Hunter KW. Tumor cell dormancy as an adaptive cell stress response mechanism. *F1000Research*. 2017, 6, 2134. DOI: 10.12688/f1000research.12174.1

- [128] Ochoa CD, Wu RF, Terada LS. ROS signaling and ER stress in cardiovascular disease. *Molecular Aspects of Medicine*. 2018, 63, 18-29. DOI: 10.1016/j.mam.2018.03.002
- [129] Hetz C, Papa FR. The unfolded protein response and cell fate control. *Molecular Cell*. 2018, 69(2), 169-181. DOI: 10.1016/j.molcel.2017.06.017
- [130] de Ridder I, Kerkhofs M, Lemos FO, Loncke J, Bultynck G, Parys JB. The ER-mitochondria interface, where Ca<sup>2+</sup> and cell death meet. *Cell Calcium*. 2023, 112, 102743. DOI: 10.1016/j.ceca.2023.102743
- [131] Casas-Martinez JC, Samali A, McDonagh B. Redox regulation of UPR signalling and mitochondrial ER contact sites. *Cellular and Molecular Life Sciences: CMLS*. 2024, 81(1), 250. DOI: 10.1007/s00018-024-05286-0
- [132] Alicea Pauneto CDM, Riesenberger BP, Gandy EJ, Kennedy AS, Clutton GT, Hem JW, et al. Intra-tumoral hypoxia promotes CD8 T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. *Immunity*. 2025, 58(10), 2489-2504.e8. DOI: 10.1016/j.immuni.2025.09.003
- [133] Dong H, Adams NM, Xu YC, Cao J, Allan DSJ, Carlyle JR, et al. The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-myc. *Nature Immunology*. 2019, 20(7), 865-878. DOI: 10.1038/s41590-019-0388-z
- [134] Jiang MS, Li X, Zhang JL, Lu YC, Shi YY, Zhu CQ, et al. Dual inhibition of endoplasmic reticulum stress and oxidation stress manipulates the polarization of macrophages under hypoxia to sensitize immunotherapy. *ACS Nano*. 2021, 15(9), 14522-14534. DOI: 10.1021/acsnano.1c04068
- [135] Mohamed E, Cao Y, Rodriguez PC. Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy. *Cancer Immunology, Immunotherapy: CII*. 2017, 66(8), 1069-1078. DOI: 10.1007/s00262-017-2019-6
- [136] Zhang C, Wang H, Li XY, Jiang YX, Sun GP, Yu HQ. Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming. *Frontiers in Oncology*. 2025, 15, 1526407. DOI: 10.3389/fonc.2025.1526407
- [137] Cognet G, Muir A. Identifying metabolic limitations in the tumor microenvironment. *Science Advances*. 2024, 10(40), eadq7305. DOI: 10.1126/sciadv.adq7305
- [138] Wang YP, Chen WJ, Wang ZD, Cai SW, Zhao XN, Jin JS, et al. Deciphering metabolic reprogramming of immune cells within the tumor microenvironment. *Journal of Translational Medicine*. 2025, 23(1), 1055. DOI: 10.1186/s12967-025-07069-y
- [139] Chuang HC, Chou CC, Kulp SK, Chen CS. AMPK as a potential anticancer target - friend or foe?. *Current Pharmaceutical Design*. 2014, 20(15), 2607-2618. DOI: 10.2174/13816128113199990485
- [140] Zhang MS, Zheng H, Zhu XQ, Liu SW, Jin H, Chen Y, et al. Synchronously evoking disulfidptosis and ferroptosis via systematical glucose deprivation targeting SLC7A11/GSH/GPX4 antioxidant axis. *ACS Nano*. 2025, 19(14), 14233-14248. DOI: 10.1021/acsnano.5c00730
- [141] Ji YK, Zhang Z, Zhao XR, Li ZY, Hu X, Zhang M, et al. IL-1 $\alpha$  facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation. *Cancer Letters*. 2024, 589, 216833. DOI: 10.1016/j.canlet.2024.216833
- [142] Xia B, Qiu LQ, Yue J, Si JX, Zhang HF. The metabolic crosstalk of cancer-associated fibroblasts and tumor cells: recent advances and future perspectives. *Biochimica et Biophysica Acta. Reviews on Cancer*. 2024, 1879(6), 189190. DOI: 10.1016/j.bbcan.2024.189190
- [143] Liu RD, Wang CD, Tao Z, Hu GY. Lipid metabolism reprogramming in cancer: insights into tumor cells and immune cells within the tumor microenvironment. *Biomedicines*. 2025, 13(8), 1895. DOI: 10.3390/biomedicines13081895
- [144] Jonker PB, Muir A. Metabolic ripple effects – deciphering how lipid metabolism in cancer interfaces with the tumor microenvironment. *Disease Models & Mechanisms*. 2024, 17(9), dmm050814. DOI: 10.1242/dmm.050814
- [145] Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. *Journal of Hematology & Oncology*. 2023, 16(1), 103. DOI: 10.1186/s13045-023-01498-2
- [146] Liu Y, Cao XT. Characteristics and significance of the pre-metastatic niche. *Cancer Cell*. 2016, 30(5), 668-681. DOI: 10.1016/j.ccell.2016.09.011
- [147] Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. *Molecular Cell*. 2020, 78(6), 1019-1033. DOI: 10.1016/j.molcel.2020.05.034
- [148] Wang HP, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. *Nature Immunology*. 2020, 21(3), 298-308. DOI: 10.1038/s41590-019-0589-5
- [149] Wu L, Zhang X, Zheng L, Zhao HK, Yan GF, Zhang Q, et al. RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis. *Cancer Immunology Research*. 2020, 8(5), 710-721. DOI: 10.1158/2326-6066.cir-19-0261
- [150] Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkova AV, Donthireddy L, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. *Nature*. 2019, 569(7754), 73-78. DOI: 10.1038/s41586-019-1118-2
- [151] Xu SH, Chaudhary O, Rodriguez-Morales P, Sun XL, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 T cells in tumors. *Immunity*. 2021, 54(7), 1561-1577.e7. DOI: 10.1016/j.immuni.2021.05.003
- [152] Niavarani SR, Lawson C, Bakos O, Boudaud M, Batenchuk C, Rouleau S, et al. Lipid accumulation impairs natural killer cell cytotoxicity and tumor control in the postoperative period. *BMC Cancer*. 2019, 19(1), 823. DOI: 10.1186/s12885-019-6045-y
- [153] Gao FX, Shah R, Xin G, Wang RN. Metabolic dialogue shapes immune response in the tumor microenvironment. *European Journal of Immunology*. 2025, 55(4), e202451102. DOI: 10.1002/eji.202451102
- [154] Ruan LQ, Wang L. Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions. *Frontiers in Oncology*. 2025, 15, 1530541. DOI: 10.3389/fonc.2025.1530541
- [155] Li RY, Huang B, Tian H, Sun ZG. Immune evasion in esophageal squamous cell cancer: from the perspective of tumor microenvironment. *Frontiers in Oncology*. 2023, 12, 1096717. DOI: 10.3389/fonc.2022.1096717
- [156] Wu SJ, Kuang HX, Ke J, Pi MF, Yang DH. Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma. *Frontiers in Oncology*. 2021, 10, 591342. DOI: 10.3389/fonc.2020.591342
- [157] Wang J, He YL, Hu FM, Hu CC, Sun YJ, Yang K, et al. Metabolic reprogramming of immune cells in the tumor microenvironment. *International Journal of Molecular Sciences*. 2024, 25(22), 12223. DOI: 10.3390/ijms252212223

- [158] Jiang MQ, Wang YC, Zhao XY, Yu JM. From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape. *Frontiers in Immunology*. 2024, 15, 1492050. DOI: 10.3389/fimmu.2024.1492050
- [159] Zhang YJ, Zhang X, Meng YT, Xu XB, Zuo DY. The role of glycolysis and lactate in the induction of tumor-associated macrophages immunosuppressive phenotype. *International Immunopharmacology*. 2022, 110, 108994. DOI: 10.1016/j.intimp.2022.108994
- [160] Yang K, Wang XK, Song CH, He Z, Wang RX, Xu YR, et al. The role of lipid metabolic reprogramming in tumor microenvironment. *Theranostics*. 2023, 13(6), 1774-1808. DOI:10.7150/thno.82920
- [161] Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. *Frontiers in Immunology*. 2021, 12, 656364. DOI: 10.3389/fimmu.2021.656364
- [162] Angeli S, Neophytou C, Kalli M, Stylianopoulos T, Mpekris F. The mechanopathology of the tumor microenvironment: detection techniques, molecular mechanisms and therapeutic opportunities. *Frontiers in Cell and Developmental Biology*. 2025, 13, 1564626. DOI: 10.3389/fcell.2025.1564626
- [163] Kureel SK, Maroto R, Davis K, Sheetz M. Cellular mechanical memory: a potential tool for mesenchymal stem cell-based therapy. *Stem Cell Research & Therapy*. 2025, 16(1), 159. DOI: 10.1186/s13287-025-04249-x
- [164] Cambria E, Coughlin MF, Floryan MA, Offeddu GS, Shelton SE, Kamm RD. Linking cell mechanical memory and cancer metastasis. *Nature Reviews. Cancer*. 2024, 24(3), 216-228. DOI: 10.1038/s41568-023-00656-5
- [165] Vela-Alcántara AM, Santiago-García J, Barragán-Palacios M, León-Chacón A, Domínguez-Pantoja M, Barceinas-Dávila I, et al. Differential modulation of cell morphology, migration, and neuropilin-1 expression in cancer and non-cancer cell lines by substrate stiffness. *Frontiers in Cell and Developmental Biology*. DOI: 10.3389/fcell.2024.1352233
- [166] L. Zhang, Y. Xiao, M. Dong, M. Li, H. Chen, and J. Wang. Three-dimensional MR elastography-based stiffness for assessing the status of Ki67 proliferation index and cytokeratin-19 in hepatocellular carcinoma. *European Radiology*. 2025, 35(8), 4722-4735. DOI: 10.1007/s00330-025-11375-w
- [167] Liu DX, Chen JJ, Zhang YF, Dai YM, Yao XZ. Magnetic resonance elastography-derived stiffness: potential imaging biomarker for differentiation of benign and malignant pancreatic masses. *Abdominal Radiology*. 2023, 48(8), 2604-2614. DOI: 10.1007/s00261-023-03956-4
- [168] Linke JA, Munn LL, Jain RK. Compressive stresses in cancer: characterization and implications for tumour progression and treatment. *Nature Reviews. Cancer*. 2024, 24(11), 768-791. DOI: 10.1038/s41568-024-00745-z
- [169] Nishi R, Oda Y, Morikura T, Miyata S. Effect of compressive stress in tumor microenvironment on malignant tumor spheroid invasion process. *International Journal of Molecular Sciences*. 2022, 23(13), 7091. DOI: 10.3390/ijms23137091
- [170] Teer L, Yaddanapudi K, Chen J. Biophysical control of the glioblastoma immunosuppressive microenvironment: opportunities for immunotherapy. *Bioengineering*. 2024, 11(1), 93. DOI: 10.3390/bioengineering11010093
- [171] Zhang YY, Zuo AN, Ba YH, Liu ST, Chen JQ, Yang SX, et al. Cancer-associated fibroblast-derived SEMA3C facilitates colorectal cancer liver metastasis via NRP2-mediated MAPK activation. *Proceedings of the National Academy of Sciences of the United States of America*. 2025, 122(21), e2423077122. DOI: 10.1073/pnas.2423077122
- [172] Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell*. 2010, 141(1), 52-67. DOI: 10.1016/j.cell.2010.03.015
- [173] LaValley DJ, Zanutelli MR, Bordeleau F, Wang W, Schwager SC, Reinhart-King CA. Matrix stiffness enhances VEGFR-2 internalization, signaling, and proliferation in endothelial cells. *Convergent Science Physical Oncology*. 2017, 3, 044001. DOI: 10.1088/2057-1739/aa9263
- [174] Gao YW, Pan ZW, Li HQ, Wang F. Antitumor therapy targeting the tumor microenvironment. *Journal of Oncology*. 2023, 2023, 6886135. DOI: 10.1155/2023/6886135
- [175] Su XD, Xie Y, Zhang JW, Li MX, Zhang Q, Jin GS, et al. HIF- $\alpha$  activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. *Cell Death & Disease*. 2022, 13(10), 861. DOI: 10.1038/s41419-022-05304-8
- [176] Deeks ED. Belzutifan: first approval. *Drugs*. 2021, 81(16), 1921-1927. DOI: 10.1007/s40265-021-01606-x
- [177] Ajnai G, Cheng CC, Kan TC, Lu JW, Rahayu S, Chiu A, et al. Improving tirapazamine (TPZ) to target and eradicate hypoxia tumors by gold nanoparticle carriers. *Pharmaceutics*. 2022, 14(4), 847. DOI: 10.3390/pharmaceutics14040847
- [178] Zhang MY, Zhu J, Bao Y, Ao Q, Mao XL, Qiu ZZ, et al. Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies. *Frontiers in Bioengineering and Biotechnology*. 2025, 13, 1589841. DOI: 10.3389/fbioe.2025.1589841
- [179] He MY, Zhang MY, Xu T, Xue SJ, Li DZ, Zhao YN, et al. Enhancing photodynamic immunotherapy by reprogramming the immunosuppressive tumor microenvironment with hypoxia relief. *Journal of Controlled Release*. 2024, 368, 233-250. DOI: 10.1016/j.jconrel.2024.02.030
- [180] Halpin-Veszeleiova K, Mallouh MP, Williamson LM, Apro AC, Botticello-Romero NR, Bahr C, et al. Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced immunosuppression. *Journal of Clinical Investigation Insight*. 2025, 10(6), e174675. DOI: 10.1172/jci.insight.174675
- [181] Budi HS, Izadi S, Timoshin A, Asl SH, Beyzai B, Ghaderpour A, et al. Blockade of HIF-1 $\alpha$  and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth. *Nanomedicine : Nanotechnology, Biology, and Medicine*. 2021, 34, 102373. DOI: 10.1016/j.nano.2021.102373
- [182] Shi CR, Liu T, Guo ZD, Zhuang RQ, Zhang XZ, Chen XY. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration. *Nano Letters*. 2018, 18(11), 7330-7342. DOI: 10.1021/acs.nanolett.8b03568
- [183] Yu YF, Liu SZ, Yang LC, Song P, Liu ZH, Liu XY, et al. Roles of reactive oxygen species in inflammation and cancer. *Medcomm*. 2024, 5(4), e519. DOI: 10.1002/mco2.519
- [184] Yang L, Dong SM, Gai SL, Yang D, Ding H, Feng LL, et al. Deep insight of design, mechanism, and cancer theranostic strategy of nanozymes. *Nano-micro Letters*. 2023, 16(1), 28. DOI: 10.1007/s40820-023-01224-0
- [185] Li ZY, Ding BB, Li J, Chen H, Zhang JS, Tan J, et al. Multi-enzyme mimetic MoCu dual-atom nanozyme triggering oxidative stress cascade amplification for high-efficiency synergistic cancer therapy. *Angewandte Chemie*. 2025, 64(1), e202413661. DOI: 10.1002/ange.202413661

- 10.1002/anie.202413661
- [186] Zeng YH, Yang JF, Gu ZX, Liu HH, Cheng YP, Peng RY, et al. Tumor microenvironment-responsive lipid peroxidation amplifier: harnessing ferroptosis resistance to devastate the ferroptosis defense system. *Analytical Chemistry*. 2025, 97(13), 7278-7288. DOI: 10.1021/acs.analchem.4c06892
- [187] Chu X, Hou HY, Duan MD, Zhang YJ, Zhu YY, Liu Y, et al. Tumor microenvironment specific regulation ca-fe-nanospheres for ferroptosis-promoted domino synergistic therapy and tumor immune response. *Small*. 2024, 20(40), e2312141. DOI: 10.1002/sml.202312141
- [188] Wu YL, Wang G, Yang RX, Zhou DF, Chen QJ, Wu QY, et al. Activation of PERK/eIF2 $\alpha$ /ATF4 signaling inhibits ER $\alpha$  expression in breast cancer. *Neoplasia*. 2025, 65, 101165. DOI: 10.1016/j.neo.2025.101165
- [189] Siwecka N, Rozpędek-Kamińska W, Wawrzynkiewicz A, Pytel D, Diehl JA, Majsterek I. The structure, activation and signaling of IRE1 and its role in determining cell fate. *Biomedicines*. 2021, 9(2), 156. DOI: 10.3390/biomedicines9020156
- [190] Asha K, Sharma-Walia N. Virus and tumor microenvironment induced ER stress and unfolded protein response: from complexity to therapeutics. *Oncotarget*. 2018, 9(61), 31920-31936. DOI: 10.18632/oncotarget.25886
- [191] Kawiak A, Kostecka A. Regulation of bcl-2 family proteins in estrogen receptor-positive breast cancer and their implications in endocrine therapy. *Cancers*. 2022, 14(2), 279. DOI: 10.3390/cancers14020279
- [192] Kurosu M, Mitachi K. DPAGT1-perspective as an anticancer drug target. *Molecules*. 2025, 30(20), 4049. DOI: 10.3390/molecules30204049
- [193] Lv GY, Sun SS, Li XY, Han RX, Liu SL, Lu M, et al. Cucurbitacin B suppresses glioblastoma via the STAT3/ROS/endoplasmic reticulum stress pathway. *Scientific Reports*. 2025, 15(1), 37485. DOI: 10.1038/s41598-025-21526-0
- [194] Cheng LY, Li HL, Xie CJ, Kuang KK, Wan BH, Chen PP, et al. Usenamine a, an RGS2 inhibitor, exerts anti-NSCLC activity and enhances cytotoxicity of gemcitabine by inducing ER stress and Notch1-mediated autophagy. *Bioorganic Chemistry*. 2025, 165, 109010. DOI: 10.1016/j.bioorg.2025.109010
- [195] Shahreza RM, Zare H, Rastegar-Pouyani N, Aria H, Hakim F, Arefnia M, et al. GRP-based vaccines as a novel approach in cancer immunotherapy: mechanisms, challenges, and prospects. *Cancer Cell International*. 2025, 25(1), 338. DOI: 10.1186/s12935-025-03979-5
- [196] Wang H, Yi ZQ, Yan S, Wang YH, Zhang WS, Guo RQ, et al. Advances in ORMDL research in malignant tumors: a review. *OncoTargets and Therapy*. 2025, 18, 821-832. DOI: 10.2147/ott.s537194
- [197] Lv BX, Zhang DD. Targeting CREBRF in cancer: mechanistic insights and future directions. *Biologics : Targets & Therapy*. 2025, 19, 341-350. DOI: 10.2147/btt.s522325
- [198] Liu LH, Li S, Qu Y, Bai H, Pan XY, Wang J, et al. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. *Cell Reports. Medicine*. 2023, 4(10), 101206. DOI: 10.1016/j.xcrm.2023.101206
- [199] Liang SY, Jiaerheng G, Huang CJ, Xie YQ, Zou XN, Liang XF, et al. An endoplasmic reticulum-targeting and calcium metabolism-disrupting nanodrug enhances tumor photodynamic immunotherapy. *Advanced Functional Materials*. 2025, 35(32), 2424108. DOI: 10.1002/adfm.202424108
- [200] Markouli M, Strepkos D, Papavassiliou KA, Papavassiliou AG, Piperi C. Crosstalk of epigenetic and metabolic signaling underpinning glioblastoma pathogenesis. *Cancers*. 2022, 14(11), 2655. DOI: 10.3390/cancers14112655
- [201] Bhutia YD, Babu E, Ganapathy V. Re-programming tumour cell metabolism to treat cancer: No lone target for lonidamine. *The Biochemical Journal*. 2016, 473(11), 1503-1506. DOI: 10.1042/bcj20160068
- [202] Inoue M, Nakagawa Y, Azuma M, Akahane H, Chimori R, Mano Y, et al. The PKM2 inhibitor shikonin enhances piceatannol-induced apoptosis of glyoxalase I-dependent cancer cells. *Genes to Cells : Devoted to Molecular & Cellular Mechanisms*. 2024, 29(1), 52-62. DOI: 10.1111/gtc.13084
- [203] Wen MK, Yi N, Mijiti B, Zhao SH, Shen GQ. N6-methyladenosine (m6A) reader HNRNPA2B1 accelerates the cervical cancer cells aerobic glycolysis. *Journal of Bioenergetics and Biomembranes*. 2024, 56(6), 657-668. DOI: 10.1007/s10863-024-10042-x
- [204] Ma YB, Wang W, Idowu MO, Oh U, Wang XY, Temkin SM, et al. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876. *Cancers*. 2018, 11(1), 33. DOI: 10.3390/cancers11010033
- [205] Song M, Kim SH, Im CY, Hwang HJ. Recent development of small molecule glutaminase inhibitors. *Current Topics in Medicinal Chemistry*. 2018, 18(6), 432-443. DOI: 10.2174/1568026618666180525100830
- [206] Pilanc-kudlek P, Cyranowski S, Wojnicki K, Ochocka N, Grzybowski M, Stańczak P, et al. 160P novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas. *Annals of Oncology*. 2019, 30(11), xi56-xi57. DOI: 10.1093/annonc/mdz452.031
- [207] Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. *Cancer Treatment Reviews*. 2022, 110, 102461. DOI: 10.1016/j.ctrv.2022.102461
- [208] Dean DJ, Falchook GS, Patel MR, Brenner AJ, Infante JR, Arkenau HT, et al. Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. *Journal Clinical Oncology*. 2016, 34(15\_suppl), 2512-2512. DOI: 10.1200/jco.2016.34.15\_suppl.2512
- [209] Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. *Nature Medicine*. 2016, 22(10), 1108-1119. DOI: 10.1038/nm.4181
- [210] Fang Y, Shen ZY, Zhan YZ, Feng XC, Chen KL, Li YS, et al. CD36 inhibits  $\beta$ -catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. *Nature Communications*. 2019, 10(1), 3981. DOI: 10.1038/s41467-019-11662-3
- [211] Pujalte-Martin M, Belaid A, Bost S, Kahi M, Peraldi P, Rouleau M, et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. *Molecular Oncology*. 2024, 18(7), 1719-1738. DOI: 10.1002/1878-0261.13583
- [212] Belouèche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. *Cancer Research*. 2017, 77(21), 5913-5924. DOI: 10.1158/0008-5472.can-16-2686
- [213] Verma S, Maniyar R, Ko M, Budhu S, Serganova I, Zappasodi R, et al. 619 pharmacologic modulation of tumor glycolysis to improve responses to immune

- checkpoint blockade therapy. *Journal Immunotherapy of Cancer*. 2021, 9(Suppl 2), A649-A649. DOI: 10.1136/jitc-2021-site2021.619
- [214] Zhang YL, Wei JY, Xu JQ, Leong WS, Liu GN, Ji TJ, et al. Suppression of tumor energy supply by liposomal nanoparticle-mediated inhibition of aerobic glycolysis. *ACS Applied Materials & Interfaces*. 2018, 10(3), 2347-2353. DOI: 10.1021/acsami.7b16685
- [215] Ni C, Li J. Take metabolic heterogeneity into consideration when applying dietary interventions to cancer therapy: a review. *Heliyon*. 2023, 9(12), e22814. DOI: 10.1016/j.heliyon.2023.e22814
- [216] Clevenger AJ, McFarlin MK, Gorley JPM, Solberg SC, Madyastha AK, Raghavan SA. Advances in cancer mechanobiology: metastasis, mechanics, and materials. *APL Bioengineering*. 2024, 8(1), 011502. DOI: 10.1063/5.0186042
- [217] Zhou HY, Wang M, Zhang YX, Su QQ, Xie ZX, Chen XY, et al. Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis. *Cancer Communications*. 2022, 42(5), 374-400. DOI: 10.1002/cac2.12294
- [218] Kang S, Lee S, Park S. iRGD peptide as a tumor-penetrating enhancer for tumor-targeted drug delivery. *Polymers*. 2020, 12(9), 1906. DOI: 10.3390/polym12091906
- [219] Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*. 2015, 112(46), 14325-14330. DOI: 10.1073/pnas.1518808112
- [220] Sun Y, Zhao W, Spriggs DR, Jain RK, Xu L. Abstract PR07: reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer. *Clinical Cancer Research*. 2020, 26 (13 Supplement), PR07. DOI: 10.1158/1557-3265.ovca19-pr07
- [221] Chen M, Xie SB. Therapeutic targeting of cellular stress responses in cancer. *Thoracic Cancer*. 2018, 9(12), 1575-1582. DOI: 10.1111/1759-7714.12890
- [222] Onwudiwe K, Najera J, Siri S, Datta M. Do tumor mechanical stresses promote cancer immune escape? *Cells*. 2022, 11(23), 3840. DOI: 10.3390/cells11233840